<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006317.pub2" GROUP_ID="COLOCA" ID="129506042711064057" MERGED_FROM="" MODIFIED="2012-05-09 10:42:00 +0100" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-05-09 11:30:45 +0200" NOTES_MODIFIED_BY="Henning Keinke Andersen" REVIEW_NO="107" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-05-09 10:58:59 +0200" MODIFIED_BY="Henning Keinke Andersen">
<TITLE MODIFIED="2010-08-05 09:13:39 +0200" MODIFIED_BY="[Empty name]">Radiofrequency ablation in the treatment of liver metastases from colorectal cancer</TITLE>
<CONTACT>
<PERSON ID="D7301B7582E26AA20144426C7AECF8B2" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roberto</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cirocchi</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher in General Surgery</POSITION>
<EMAIL_1>cirocchiroberto@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Surgery</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Terni</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 3290 1388 38</PHONE_1>
<PHONE_2/>
<FAX_1>+39 0744 2052 01</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-05-09 10:57:36 +0200" MODIFIED_BY="Henning Keinke Andersen">
<PERSON ID="D7301B7582E26AA20144426C7AECF8B2" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roberto</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cirocchi</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher in General Surgery</POSITION>
<EMAIL_1>cirocchiroberto@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Surgery</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Terni</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 3290 1388 38</PHONE_1>
<PHONE_2/>
<FAX_1>+39 0744 2052 01</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="45469605757859089705100318102718" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Stefano</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Trastulli</LAST_NAME>
<SUFFIX/>
<POSITION>Resident in General Surgery</POSITION>
<EMAIL_1>stefano.trastulli@hotmail.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Surgery</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Perugia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0744/205201</PHONE_1>
<PHONE_2/>
<FAX_1>+39 0744/205201</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="27141809011301337295100722141151" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carlo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Boselli</LAST_NAME>
<SUFFIX/>
<POSITION>Academic Research</POSITION>
<EMAIL_1>carloboselli@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+393474963953</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of General Surgery</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Perugia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+393474963953</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9AEC366382E26AA201E6E48B62121A66" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alessandro</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Montedori</LAST_NAME>
<SUFFIX/>
<POSITION>Public Health Expert</POSITION>
<EMAIL_1>amontedori@regione.umbria.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Health Planning Service</DEPARTMENT>
<ORGANISATION>Regional Health Authority of Umbria</ORGANISATION>
<ADDRESS_1>Via Mario Angeloni 61</ADDRESS_1>
<ADDRESS_2/>
<CITY>Perugia</CITY>
<ZIP>06124</ZIP>
<REGION>Umbria</REGION>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 075 5045217</PHONE_1>
<PHONE_2/>
<FAX_1>+39 075 5045569</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="55415410911953547300111212145358" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Davide</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cavaliere</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>cavalied@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+393485834372</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Surgical Oncology</DEPARTMENT>
<ORGANISATION>Forlì Hospital</ORGANISATION>
<ADDRESS_1>Via C. Forlanini, 34</ADDRESS_1>
<ADDRESS_2/>
<CITY>Forlì</CITY>
<ZIP>47121</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="33162643974562860667120312095555" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Amilcare</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Parisi</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>amilcareparisi@virgilio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Liver Unit and Department of Digestive Surgery</DEPARTMENT>
<ORGANISATION>Hospital of Terni</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Terni</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="63244841233764279825100722141604" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Giuseppe</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Noya</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>gnoya@unipg.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Surgery</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Perugia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6817165D82E26AA201DBBAAB29D7F431" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Iosief</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Abraha</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>iosief_a@yahoo.it</EMAIL_1>
<EMAIL_2>iabraha@regione.umbria.it</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiology Department</DEPARTMENT>
<ORGANISATION>Regional Health Authority of Umbria</ORGANISATION>
<ADDRESS_1>Via Mario Angeloni, 61</ADDRESS_1>
<ADDRESS_2/>
<CITY>Perugia</CITY>
<ZIP>06124</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 075 5045251</PHONE_1>
<PHONE_2>+39 349 0770910</PHONE_2>
<FAX_1>+39 075 5045569</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-05-09 10:58:59 +0200" MODIFIED_BY="Henning Keinke Andersen">
<UP_TO_DATE>
<DATE DAY="1" MONTH="2" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="8" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="6" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2011-09-16 22:59:42 +0200" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2010-08-23 12:13:31 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-23 10:51:59 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-08-03 12:00:58 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-05-09 11:30:45 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-03-21 13:28:19 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-09-10 21:59:42 +0200" MODIFIED_BY="[Empty name]">Should radiofrequency ablation be used in patients with liver colorectal metastases? </TITLE>
<SUMMARY_BODY MODIFIED="2012-03-21 13:28:19 +0100" MODIFIED_BY="[Empty name]">
<P>Colorectal cancer is one of the most common malignant tumour worldwide and approximately 50 % of patients will develop liver metastases (liver is the first site of metastatic disease). Hepatic resection is the only curative option, but only 15-20% of patients with liver metastases from colorectal cancer are suitable for surgical standard treatment. Besides chemotherapy, several minimally invasive treatment techniques have been developed to treat patients with CRLMs: hepatic arterial infusion, cryotherapy, microwave ablation, selective internal radion treatment, radiofrequency ablation. During the past decade radiofrequency ablation has superseded other ablative therapies, due to its low morbidity, mortality, safety and patient acceptability. Radiofrequency ablation is a minimally invasive technique in which a needle is inserted into the tumour (liver metastases) either getting access by way of the skin (percutaneously) or via open approach (surgically). Alternating current is generated using radio waves and, through needle, create local tissue temperatures of 50-100&#730;C temperature, that causes &#8220;coagulation&#8221; and tumour necrosis. According to several studies RFA is technically feasible and safe for the treatment of CRLMs, however little is known about its efficacy in terms of overall survival (OS), disease free survival (DFS) and local recurrence. The aim of this review was to see if the treatment of CRLMs with RFA provides more benefit in terms of overall survival, disease free survival and local recurrence. This review include 18 studies (10 observational studies, 7 CCTs and an additional 1 RCT) comparing radiofrequency ablation with any other treatment. The heterogeneity regarding interventions, comparisons and outcomes rendered the data unusable and unsuitable for drawing conclusions. There is insufficient evidence to recommend the use of radiofrequency ablation for a radical treatment of liver metastases from colorectal cancer. High quality randomised clinical trials are required to answer on the potential benefit and harms associated with the use of radiofrequency ablation in the treatment of liver metastases from colorectal cancer.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-05-09 11:27:15 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-01-05 19:12:11 +0100" MODIFIED_BY="[Empty name]">
<P>Colorectal cancer (CRC) is the most common malignant tumour and the third leading cause of cancer deaths in USA. For advanced CRC, the liver is the first site of metastatic disease; approximately 50 % of patients with CRC will develop liver metastases either synchronously or metachronously within 2 years after primary diagnosis. Hepatic resection (HR) is the only curative option, but only 15-20% of patients with liver metastases from CRC (CRLMs) are suitable for surgical standard treatment. In patients with unresectable CRLMs downsizing chemotherapy can improve resectability (16%). Modern systemic chemotherapy represents the only significant treatment for unresectable CRLMs. However several loco-regional treatments have been developed: hepatic arterial infusion (HAI), cryosurgical ablation (CSA), radiofrequency ablation (RFA), microwave ablation and selective internal radion treatment (SIRT). During the past decade RFA has superseded other ablative therapies, due to its low morbidity, mortality, safety and patient acceptability.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-05-09 11:27:15 +0200" MODIFIED_BY="[Empty name]">
<P>The objective of this study was to systematically review the role of radiofrequency ablation (RFA) in the treatment of CRLMs.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-01-04 16:56:20 +0100" MODIFIED_BY="[Empty name]">
<P>We performed electronic searches in the following databases:CENTRAL, MEDLINE and EMBASE. Current trials were identified through the Internet using the Clinical-Trials.gov site (to January 2, 2012) and ASCO Proceedings. The reference lists of identified trials were reviewed for additional studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-05-09 11:24:05 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized clinical trials (RCTs), quasi-randomised or controlled clinical trials (CCTs) comparing RFA to any other therapy for CRLMs were included. Observational study designs including comparative cohort studies comparing RFA to another intervention, single arm cohort studies or case control studies have been included if they have: prospectively collected data, ten or more patients; and have a mean or median follow-up time of 24 months. Patients with CRLMs who have no contraindications for RFA. Patients with unresectable extra-hepatic disease were also included.Trials have been considered regardless of language of origin.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-03-21 13:25:31 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 1144 records were identified through the above electronic searching. We included 18 studies: 10 observational studies, 7 Clinical Controlled Trials (CCTs) and an additional 1 Randomized Clinical Trial (RCT) (abstract) identified by hand searching in the 2010 ASCO Annual Meeting. The most appropriate way of summarizing time-to-event data is to use methods of survival analysis and express the intervention effect as a hazard ratio. In the included studies these outcome are mostly reported as dichotomous data so we should have asked authors research data for each participant and perform Individual Patient Data (IPD) meta-analysis. Given the study design and low quality of included studies we decided to give up and not to summarize these data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-05-09 11:22:01 +0200" MODIFIED_BY="[Empty name]">
<P>Seventeen studies were not randomised and this increases the potential for selection bias. In addition, there was imbalance in the baseline characteristics of the participants included in all studies. All studies were classified as having a elevate risk of bias. The assessment of methodological quality of all non-randomized studies included in meta-analysis performed by the STROBE checklist has allowed us to identify several methodological limits in most of the analysed studies. At present, the information from the single RCT included (<A HREF="Ruers 2010">Ruers 2010</A>) comes from an abstract of 2010 ASCO Annual Meeting where the allocation concealment was not reported; however in original protocol allocation concealment was adequately reported (<A HREF="EORTC 40004 protocol">EORTC 40004 protocol</A>). The heterogeneity regarding interventions, comparisons and outcomes rendered the data not suitable.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-03-21 13:27:49 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review gathers information from several controlled clinical trials and observational studies which are vulnerable to different types of bias. The imbalance between characteristics of patients in the allocated groups appears to be the main concern. Only one randomised clinical trial (published as an abstract), comparing 60 patients receiving RFA plus CT versus 59 patients receiving CT alone, was identified. This study showed that PFS was significantly higher in the group that received RFA. However, it was not able to provide information on overall survival. In conclusion, evidence from the included studies are insufficient to recommend RFA for a radical oncological treatment of CRLMs.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-05-09 11:30:45 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-05-09 11:28:48 +0200" MODIFIED_BY="[Empty name]">
<P>Colorectal cancer (CRC) is the most common malignant tumour and the third leading cause of cancer deaths in USA. During the past two decades, a decrease in incidence rates has been observed (from 66.3 cases in 1985 to 45.5 cases per 100,000 persons in 2006 ), and could be explained by increases of screening tests and the removal of polyps before they growth to cancer (<LINK REF="REF-American-Cancer-Society-2010" TYPE="REFERENCE">American Cancer Society 2010</LINK>). For advanced CRC, the liver is the first site of metastatic disease (<LINK REF="REF-Weiss-1986" TYPE="REFERENCE">Weiss 1986</LINK>); approximately 50 % of patients with CRC will develop liver metastases either synchronously or metachronously within 2 years after primary diagnosis (<LINK REF="REF-Schindl-2008" TYPE="REFERENCE">Schindl 2008</LINK>). Hepatic resection (HR) is the only curative option, but only 15-20% of patients with liver metastases from CRC (CRLMs) are suitable for surgical standard treatment (<LINK REF="REF-Garden-2006" TYPE="REFERENCE">Garden 2006</LINK>). In patients with unresectable CRLMs downsizing chemotherapy can improve resectability (16%) (<LINK REF="REF-Adam-2009" TYPE="REFERENCE">Adam 2009</LINK>). Modern systemic chemotherapy represents the only significant treatment for unresectable CRLMs (<LINK REF="REF-Adam-2004" TYPE="REFERENCE">Adam 2004</LINK>). However several loco-regional treatments have been developed: hepatic arterial infusion (<LINK REF="REF-Idelevich-2009" TYPE="REFERENCE">Idelevich 2009</LINK>), cryotherapy (<LINK REF="REF-Xu-2008" TYPE="REFERENCE">Xu 2008</LINK>), radiofrequency ablation (RFA) (<LINK REF="REF-Feliberti-2006" TYPE="REFERENCE">Feliberti 2006</LINK>), microwave ablation (<LINK REF="REF-Boutros-2010" TYPE="REFERENCE">Boutros 2010</LINK>) and selective internal radion treatment (SIRT) (<LINK REF="REF-Gray-2001" TYPE="REFERENCE">Gray 2001</LINK>).</P>
<P>During the past decade radiofrequency ablation (RFA) has superseded other ablative therapies (<LINK REF="REF-Goldberg-1998" TYPE="REFERENCE">Goldberg 1998</LINK>), due to its low morbility (8.9%) (<LINK REF="REF-Mulier-2005" TYPE="REFERENCE">Mulier 2005</LINK>), mortality (0.5%) (<LINK REF="REF-Mulier-2005" TYPE="REFERENCE">Mulier 2005</LINK>), safety and patient acceptability. A RFA needle is inserted into the tumour either percutaneously or surgically (via the laparoscopic or open approach). Alternating current is generated using radio waves and, through RFA needle, create local tissue temperatures of 50-100&#730;C temperature for at least 4-6 minutes (<LINK REF="REF-Lencioni-2009" TYPE="REFERENCE">Lencioni 2009</LINK>), that causes &#8220;coagulation&#8221; (<LINK REF="REF-Lencioni-2005" TYPE="REFERENCE">Lencioni 2005</LINK>) and tumour necrosis (<LINK REF="REF-Decadt-2004" TYPE="REFERENCE">Decadt 2004</LINK>; <LINK REF="REF-McGahan-1996" TYPE="REFERENCE">McGahan 1996</LINK>; <LINK REF="REF-Solbiati-1997" TYPE="REFERENCE">Solbiati 1997</LINK>); usually the duration of RFA is 10-30 minutes for the slow conduction from the RFA needle electrode through the tumour (<LINK REF="REF-Lencioni-2009" TYPE="REFERENCE">Lencioni 2009</LINK>). To reduce the incidence of local tumour recurrence after RFA, a 1-cm-thick tumor-free margin along each tumour is necessary, which can be achieved by multiple overlapping ablations or modified RFA devices (<LINK REF="REF-Lencioni-2009" TYPE="REFERENCE">Lencioni 2009</LINK>). At present, new modified RFA devices are available: a multi-pled expandable electrode with multiple retractable prongs on the tip (AngioDynamics/RITA Medical Systems) and an internally cooled electrode (Radionics, Tyco Healthcare Group, Burlington, MA) (<LINK REF="REF-Lencioni-2005" TYPE="REFERENCE">Lencioni 2005</LINK>).</P>
<P>Tumor size and localization are important factors for successfully ablation treatment, such as smaller colorectal derived oligometastasis isolated to the liver less than 3 cm in diameter (<LINK REF="REF-Lencioni-2009" TYPE="REFERENCE">Lencioni 2009</LINK>), surrounded by liver parenchyma, 1 cm or more deep to the liver glissonian, and &#8805; 2 cm from large liver veins (<LINK REF="REF-Goode-2005" TYPE="REFERENCE">Goode 2005</LINK>). Data on long-term survival (5-year OS), after different methods of RFA, have been reported with a range between 22-30% (<LINK REF="REF-Gillams-2004" TYPE="REFERENCE">Gillams 2004</LINK>; <LINK REF="REF-Lencioni-2004" TYPE="REFERENCE">Lencioni 2004</LINK>; <LINK REF="REF-Machi-2006" TYPE="REFERENCE">Machi 2006</LINK>; <LINK REF="REF-Veltri-2008" TYPE="REFERENCE">Veltri 2008</LINK>). There is a 5-year OS increasing (40%) in small (&#8804;4 cm) solitary CRLM (<LINK REF="REF-Gillams-2008" TYPE="REFERENCE">Gillams 2008</LINK>).</P>
<P>To date, multiple articles have reviewed the outcomes of RFA for CRLMs (<LINK REF="REF-Decadt-2004" TYPE="REFERENCE">Decadt 2004</LINK>; <LINK REF="REF-Erce-2003" TYPE="REFERENCE">Erce 2003</LINK>; <LINK REF="REF-Garcea-2003" TYPE="REFERENCE">Garcea 2003</LINK>; <LINK REF="REF-Lau-2003" TYPE="REFERENCE">Lau 2003</LINK>; <LINK REF="STD-Sutherland-2006" TYPE="STUDY">Sutherland 2006</LINK>). Six of these studies were systematic reviews that examined the outcomes of RFA for CRLMs (<LINK REF="STD-Sutherland-2006" TYPE="STUDY">Sutherland 2006</LINK>; <LINK REF="REF-Mulier-2005" TYPE="REFERENCE">Mulier 2005</LINK>; <LINK REF="REF-Mulier-2008a" TYPE="REFERENCE">Mulier 2008a</LINK>; <LINK REF="REF-Mulier-2008b" TYPE="REFERENCE">Mulier 2008b</LINK>; <LINK REF="STD-Stang-2009" TYPE="STUDY">Stang 2009</LINK>; <LINK REF="STD-Wong-2010" TYPE="STUDY">Wong 2010</LINK>).</P>
<P>The recent review of American Society of Clinical Oncology (ASCO) searched the literature until April 2007 and examined the broader subject of RFA for CRLMs (<LINK REF="STD-Wong-2010" TYPE="STUDY">Wong 2010</LINK>). This review came to identical conclusions as from Mulier's reviews: the increased recurrence rates are related to the diameter of tumours, the location of tumours, the approach used to perform RFA (open, laparoscopic, or percutaneous) and the physician experience. This review also analysed the use of RFA in CRLMs with extrahepatic disease: no difference in terms of survival resulted in patients with extrahepatic disease compared with patients with no extrahepatic disease (P = 0.34) (<LINK REF="REF-Siperstein-2007" TYPE="REFERENCE">Siperstein 2007</LINK>).</P>
<P>Recently there has been an increased tendency to use RFA for unresectable CRLMs down staged by chemotherapy (CT) (<LINK REF="REF-Knudsen-2009" TYPE="REFERENCE">Knudsen 2009</LINK>). At the 2010 ASCO Annual Meeting, Ruers and coauthors (<LINK REF="STD-Ruers-2010" TYPE="STUDY">Ruers 2010</LINK>) presented the final results of the EORTC inter group randomised study 40004 (CLOCC), evaluating the benefits of adding RFA to CT alone (FOLFOX, oxaliplatin 85 mg/m<SUP>2</SUP> and LV5FU2, and since October 2005 plus bevacizumab) vs RFA plus CT in patients with &#8804; 9 unresectable CRC LM and no extrahepatic disease. At a median follow up of 4.4 years, the 30-months OS rate was 61.7% (95% CI, 48.21-73.93) in the RFA + CT group and 57.6% (44.07-70.39) in the CT group (<LINK REF="STD-Ruers-2010" TYPE="STUDY">Ruers 2010</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-05-09 11:30:45 +0200" MODIFIED_BY="[Empty name]">
<P>The objective of this study was to systematically review the role of radiofrequency ablation (RFA) in the treatment of Liver Metastases from ColoRectal cancer (CRLMs).</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-05-08 11:38:30 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-07-14 11:18:03 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-07-14 11:18:03 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized clinical trials (RCTs) or quasi-randomised of RFA compared to any other therapy for CRLMs were included. Acceptable quasi-randomisation methods were the use of alternate patient assignment including allocation by day of week, birth date or hospital record number. Observational study designs including comparative cohort studies comparing RFA to another intervention, single arm cohort studies or case control studies have been included if they have: prospectively collected data, ten or more patients; and have a mean or median follow-up time of 24 months. Trials have been considered regardless of language of origin.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-07-07 09:59:30 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with CRLMs who have no contraindications for RFA. Patients with unresectable extra-hepatic disease, too, have been included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-07-07 10:01:55 +0200" MODIFIED_BY="[Empty name]">
<P>The intervention of interest is RFA alone or in combination to other interventions compared to any other intervention. We planned to allow co-interventions if carried out equally in the trial groups. All technologies for RFA were examined. All routes of RFA administration (i.e. percutaneous, laparoscopic or open surgery) were considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-07-03 23:36:13 +0200" MODIFIED_BY="[Empty name]">
<P>Studies that include one or more of the following outcomes were assessed:</P>
<P>1. Overall survival (OS) at 2, 3, or 5 years.<BR/>2. Disease-free survival (DFS) at 1, 2 and 5 years.<BR/>3. Local recurrence at 1 and 2 years.<BR/>4. Treatment efficacy: proportion of patient with residual disease following treatment.<BR/>5. Procedure related complications/adverse events; either minor complications (cautery burns, skin injury), or major complications (bleeding requiring transfusion or directed therapy, liver failure, bile duct injury requiring intervention, damage to surrounding viscera, intra-abdominal sepsis, needle tract tumour seeding, wound infection).<BR/>6. Procedure related mortality (by 30 days or during the same hospitalisation)</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-01-03 19:24:09 +0100" MODIFIED_BY="[Empty name]">
<P>We performed a electronic searches in the following databases:</P>
<P>The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). Current trials were identified through the Internet using the Clinical Trials.gov site (to January 2, 2012) and ASCO Proceedings. The bibliographies of identified trials were reviewed for additional studies.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-05-08 11:38:30 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Selection of trials<BR/>
</I>
</B>The titles and abstracts of all potentially relevant trials were screened by one reviewer (CR and GN). The full text articles of potentially relevant studies were obtained. Based on the full text article, two reviewers (CB and NG) independently determined whether the study meets the inclusion/exclusion criteria. A third author (ST) independently assessed any discordant results. Discrepancies was resolved through discussion.</P>
<P>Inclusion criteria for RCTs were:<BR/>1. Patients with CRLMs<BR/>2. RFA to the liver<BR/>3. One or more of the outcome measures reported<BR/>4. Data must have been reported on a per patient basis (not per lesion)</P>
<P>Inclusion criteria for observational studies were:<BR/>1. Prospectively collected data<BR/>2. Sample size of &#8805; 10 patients (per group)<BR/>3. Follow-up (mean or median) period of &#8805; 24 months<BR/>4. Patients with liver metastases from CRC<BR/>5. RFA to the liver<BR/>6. One or more of the outcome measures reported<BR/>7. Data must have been reported on a per patient basis (not per lesion)<BR/>
<B>
<I>
<BR/>Methodological quality of included studies<BR/>
</I>
</B>Two reviewers (CR and AP) assessed the methodological quality of the trials independently. For RCTs, the component approach was used to assess study quality (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>). Components that was assessed include: the generation of randomizations sequence, adequacy of allocation concealment and the adequacy of follow-up. Each trial was classified as: adequate, unclear or inadequate.</P>
<P>Given the difficulty of blinding of an invasive procedure, blinding for intervention was not included in the assessment of methodological quality. Since the primary outcome for this study was overall survival, and this measure was minimally affected by bias, blinding of outcome assessment was not included in the assessment of study quality (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>).</P>
<P>Observational studies were assessed for quality using an analogous component approach (<LINK REF="REF-Stroup-2000" TYPE="REFERENCE">Stroup 2000</LINK>). These components were adapted from checklist by Tooth et al (<LINK REF="REF-Tooth-2005" TYPE="REFERENCE">Tooth 2005</LINK>). Components that were assessed include: clear specification of eligibility criteria, attempt to adjust for confounding, and adequacy of follow-up. Studies were categorized as: adequate, unclear or inadequate.</P>
<P>
<B>
<I>Data extraction<BR/>
</I>
</B>Trial data were extracted by each author (IA and AM) independently. Any discrepancies were resolved by a third author (DC). For trials that include patients with multiple diagnoses, data were extracted for patients with CRLMs.<BR/>
<B>
<I>
<BR/>Statistical analysis<BR/>
</I>
</B>All statistical analyses were performed on an intention-to-treat basis. Analysis were performed on a per patient basis. Statistical methods included analysis using both relative risk and odds ratio. In addition, time to event analyses were performed when possible. A summary hazard ratio were extracted for each study (when possible), and combined into an overall summary estimate using the methods of Whitehead et al (<LINK REF="REF-Whitehead-1991" TYPE="REFERENCE">Whitehead 1991</LINK>).</P>
<P>Fixed effects and the random effects models were both tested. If these results were not significantly different, the fixed effects model was reported. The Q test was used to test for heterogeneity between studies. Heterogeneity was quantified using I<SUP>2</SUP> statistics. Data were displayed with Forest plots. Statistical significance was set as P = 0.10 for testing heterogeneity, and P=0.05 for all other analyses.</P>
<P>Subgroup analyses include: number of metastatic lesions treated by RFA, &lt; or &#8805; 4 cm size of the largest metastatic lesion, surgical vs. percutaneous approach for RFA, and the presence or absence of co-interventions.</P>
<P>Sensitivity analyses were planned to examine the influence of each individual trial and the influence of trial quality on the results of the meta-analysis. Publication bias were examined using funnel plots.</P>
<P>All analyses were performed using the RevMan Analyses version 5.0.23 (integrated in the Review Manager software provided by the Cochrane Collaboration).</P>
<UNIT_OF_ANALYSIS MODIFIED="2012-05-08 11:38:30 +0200" MODIFIED_BY="[Empty name]">
<P>Cross-over and cluster randomised trials were not anticipated in this review. We avoided double-counting of participants where there were multiple interventions in the same trial.</P>
</UNIT_OF_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-03-21 13:29:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-03-21 13:29:30 +0100" MODIFIED_BY="[Empty name]">
<P>The PRISMA flow diagram for systematic reviews is presented in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>).  A total of 1144 records were identified through the above electronic searching. We included 18 studies: 10 observational studies, 5 CCTs and an additional 1 RCT (abstract) identified by hand searching in the 2010 ASCO Annual Meeting.</P>
<P>
<B>RFA versus HR</B>
</P>
<P>Seven observational studies and six CCTs were included. The characteristics of all trials included in this review are listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>A CCT (<LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>) compared 25 patients who underwent RFA with 20 who received HR in treatment of solitary CRLMs. RFA was used in extrahepatic disease (7 patients), vessel contiguity (9 patients) and co-morbidity (9 patients). The patients that underwent liver resection, had no evidence of extrahepatic disease. Twenty-two patients, in group underwent RFA, and 17 patients, in group underwent surgical treatment, received systemic chemotherapy. RF ablation was performed percutaneously with ultrasonographic and CT or magnetic resonance guidance.</P>
<P>A study on a prospective hepatobiliary database of Department of Surgical Oncology at the University of Texas M. D. Anderson Cancer Center, Houston (<LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK>) compared 30 patients who underwent RFA with 150 who received HR for the treatment of solitary CRLMs. RFA was used when HR would have not left an adequate hepatic residual parenchyma (20 patients) or the comorbidity precluded adequate HR (10 patients: 3 were treated percutaneously in the operating room under general anaesthesia by a hepatic surgeon and 7 were treated at open laparotomy). All of the patients treated with RFA had lesions proven to be metastases based on classic imaging findings on computed tomography (hypodense lesion with rim enhancement during the arterial contrast phase).There was no statistical difference in the use of chemotherapy between the RFA (80%) and HR (66%) groups (P=.32).<BR/>
</P>
<P>A study on a prospective colorectal cancer database of Department of Surgery in the University of Ulsan College of Medicine, Seoul, Korea (<LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK>) compared 30 patients who underwent RFA with 59 that received HR for CRLMs. RFA was used when HR were not feasible for co-morbidity, when patients avoided surgical treatment or when hepatic residual parenchyma after HR was not adequate. RFA was executed percutaneously using ultrasonographic and computed tomography guidance in local anaesthesia. Clinicopathological characteristics of patients, primary tumours and the frequency of use of chemotherapy (22 pts in RFA and 48 pts in HR group) were not different.</P>
<P>A CCT of Department of Surgical Oncology in Memorial Sloan-Kettering Cancer Center New York (<LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>) compared 22 patients that underwent RFA with 30 that received HR for the treatment of solitary CRLMs. The indications for treatment with RFA were the same of precedent studies except prior major hepatectomy (50% of patients). Most of patients in both groups received chemotherapy.</P>
<P>A study on a prospective colorectal cancer database at Samsung Medical Center, Seoul, Korea (<LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>) reported 37 patients treated with RFA and 116 with HR. The indication for RFA were: refusal of HR, insufficient hepatic reserve for surgery on Indocyanine Green test, and co-morbidities such as severe chronic obstructive pulmonary disorder, congestive heart failure. The proportion of patients who received post-RFA or post-HR chemotherapy was similar between the 2 groups (89.2% and 87.9%; P=0.836).<BR/>
</P>
<P>A study on a prospective database of The Johns Hopkins Hospital, Baltimore, Maryland (<LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>) compared 11 patients underwent RFA alone vs 192 HR alone vs 55 RFA + HR. Only patients who were operated on with curative intent and undergoing their first liver-directed therapy were included in the study. Only RFA treatments that were performed at the time of open laparotomy were included; patients who underwent percutaneous or laparoscopic-assisted RFA were excluded. Patients were treated with RFA alone or in combination with HR when the LMs were considered unresectable because of location of the disease, inadequate liver remnant, proximity of tumour to major vascular structures, or the presence of medical co-morbidities that precluded major hepatic resection. Tumors were considered for RFA if near a major hepatic vein branch but not if adjacent to major biliary structures near the liver hilum. The proportion of patients who received preoperative systemic chemotherapy post-RFA alone or post-RFA + HR or post-HR alone was respectively (54.5%, 65.5% and 38.0%; P=0.001).<BR/>
</P>
<P>A CCT of Cleveland Clinic (Cleveland, OH, USA) (<LINK REF="STD-Berber-2008" TYPE="STUDY">Berber 2008</LINK>) evaluated 68 patients underwent RFA and 90 underwent HR for solitary liver metastasis from colorectal cancer. The RFA was performed for patient co-morbidities, extra-hepatic disease, patient decision and a combination of these. There was no statistical difference in the use of preoperative chemotherapy between the RFA (82%) and HR (72%) groups (P=0.6).</P>
<P>A study on a prospective database of a Colorectal Cancer Clinic of Yonsei University College of Medicine (Seoul, Korea) (<LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK>) compared 25 patients who underwent RFA with 42 underwent HR in treatment of solitary CRLMs. RFA was used when there were not indications for surgical treatment (LM near to or involving the major vessels, insufficient residual parenchyma after HR, severe co-morbidities or the patients want to be treated with RFA). There was no difference in the use of chemotherapy between the RFA (88.1%) and HR (88%) treatment groups.<BR/>
</P>
<P>In <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK> CCT study's there is a retrospective analysis of 190 patients with liver metastases of colorectal carcinoma treated at 2° Surgical Department of University Hospital in Olomouc, Czech Republic: RFA alone in 31 patients, HR alone in 136 and RFA combined with HR in 23 patients. All patients underwent adjuvant chemotherapy.<BR/>
</P>
<P>A study on a prospective database of Department of Surgery of University of Manitoba (Manitoba Province, Canada) (<LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK>), compared 43 patients who underwent RFA with 58 who received HR and with 12 pts who received RFA plus HR in treatment of CRLMs. The patients who underwent RFA had unresectable disease. Authors did not state to determine the exact reason why the disease was unresectable in each case. RFA was performed as an open procedure in all cases. Systemic chemotherapy was administered at the discretion of the medical oncologists.</P>
<P>A study on a prospective database of a Department of Surgery, University of Louisville, Kentucky USA (<LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>) compared 46 patients who underwent RFA with 94 who received HR in treatment of solitary CRLMs. All patients who underwent RFA were considered to have unresectable disease. Systemic chemotherapy was administered at the discretion of the medical oncologist.<BR/>
</P>
<P>The other prospective CCT, conducted at the Departments of Transplantation and Hepatobiliopancreatic Surgery and Diagnostic and Interventional Radiology, Johannes Gutenberg University of Mainz, Mainz, Germany, compared 28 patients underwent RFA vs 82 underwent HR (<LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>). Indications for RFA were completely different from those of previous studies. The RFA was performed in CRLMs founded within the first year after colorectal resection; otherwise the HR was performed in patients in whom RFA was not possible for number, diameter, or location of CRLMs.</P>
<P>A analysis on a prospective database of Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea) (<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>) compared 177 patients underwent RFA, 278 underwent HR for CRLM and 27 underwent combination therapy for CRLM. RFA was performed in cases unresectable for severe co-morbidities, difficult site for HR, and more than four LMs.</P>
<P>
<B>RFA plus systemic chemotherapy versus systemic chemotherapy alone</B>
<BR/>
</P>
<P>A single multicenter RCT (<LINK REF="STD-Ruers-2010" TYPE="STUDY">Ruers 2010</LINK>), conducted in four European countries (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>), compared RFA plus CT (6 months FOLFOX, oxaliplatin 85 mg/m<SUP>2</SUP> and LV5FU2, plus, since<SUP> </SUP>October 2005, bevacizumab) with CT alone in the first line treatment of metastatic colorectal in 119 patients (60 pts. underwent RFA plus CT vs 59 underwent CT alone). This study included patients with &#8804;9 unresectable CRCLMs and no extrahepatic<SUP> </SUP>disease. In this study RFA was performed by laparotomy, laparoscopy or percutaneously (<LINK REF="REF-EORTC-40004-protocol" TYPE="REFERENCE">EORTC 40004 protocol</LINK>).</P>
<P>
<B>RFA plus adjuvant hepatic arterial infusion chemotherapy (HAI) versus RFA plus adjuvant HAI plus HR</B>
</P>
<P>A CCT (<LINK REF="STD-Scaife-2003" TYPE="STUDY">Scaife 2003</LINK>) conducted at the University of Texas M. D. Anderson Cancer Center, Houston, TX, and the G. Pascale National Tumor Institute, Naples, Italy, compared 19 patients underwent RFA plus adjuvant HAI (continuous-infusion floxuridine, 0.1 mg/kg days 1&#8211;7, and bolus fluorouracil, 12.5 mg/kg days 15, 22 and 29) without hepatic resection (HR) versus 31 RFA plus adjuvant HAI plus HR in the first line treatment of metastatic colorectal. RFA was performed during the open surgical treatment (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>
<B>RFA alone vs RFA plus HR vs HR alone vs chemotherapy alone</B>
</P>
<P>A single observational study (<LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>) compared 57 RFA alone vs 101 RFA plus HR vs 190 HR alone vs 70 chemiotherapy alone (systemic, intraarterial via hepatic artery infusion pump placed at the index laparotomy, or intraarterial plus systemic chemotherapy). RFA alone or in association with HR was limited to cases in whom resection did not permit complete resection without leaving adequate liver parenchyma. All patients underwent resection and/or RFA during open laparotomy (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
<P>
<B>RFA plus HR vs HR plus CSA (cryosurgical ablation)</B>
</P>
<P>A single observational study (<LINK REF="STD-Kornprat-2007" TYPE="STUDY">Kornprat 2007</LINK>) compared intraoperative RFA plus HR (19 pts.) vs intraoperative CSA plus HR (20 pts.) combined with hepatic resection in extensive CRLMs (5 median). There was no difference in median size of LM underwent CSA and RFA (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
<P>
<B>RFA vs RFA plus HR</B>
</P>
<P>
<LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK> compared 43 patients that underwent RFA vs 12 that underwent RFA and hepatic resection in treatment of CRLMs. The patients receiving RFA alone or in combination with resection had unresectable disease. In this trial is not stated the reason why the CRLMs were unresectable. Other studies are <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>, that compared 11 patients underwent RFA alone vs 55 RFA plus HR and 192 HR, <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK>, that compared 31 patients underwent RFA alone vs 136 underwent HR and 23 underwent RFA combined with HR, and <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>, that analysed 177 patients underwent RFA and 27 underwent combination therapy for CRLM (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-09-30 14:45:13 +0200" MODIFIED_BY="[Empty name]">
<P>All studies were classified as having a elevate risk of bias. The assessment of methodological quality of all non-randomized studies included in meta-analysis performed by the 22 items and the STROBE checklist has allowed us to identify several methodological limits in most of the analysed studies (<LINK REF="REF-Vandenbroucke-2007" TYPE="REFERENCE">Vandenbroucke 2007</LINK>) (<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>).</P>
<P>In particular the <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>, <LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>, <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>, <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>, <LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK>, <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>, <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK> and <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK> studies do not indicates the study design on the title and in the abstract (Item 1). Two studies (<LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK> and <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>) do not show the key elements of study design early in the paper (Item 4). Six included studies show problems in the setting (Item 5). Particularly the studies by <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>, <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK> and <LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK> do not describes in the methods sections the locations of the study,  while periods of recruitment and exposure of the patients are not reported in the studies by <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>, <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK> and <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK>.</P>
<P>The follow-up time as not indicated in the <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>, <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>, <LINK REF="STD-Kornprat-2007" TYPE="STUDY">Kornprat 2007</LINK>, <LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK> and <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK> studies. <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>, <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK> e <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK> in their paper do not show the data collection period. With regard to Item 7 (variables) we found the lack of a clear definitions of analysed outcomes in the <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>, <LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>, <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK> and <LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK> studies, the lack of  clear definitions of the predictors factors in the study of <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>, <LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>, <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>, <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>, <LINK REF="STD-Kornprat-2007" TYPE="STUDY">Kornprat 2007</LINK>, <LINK REF="STD-Berber-2008" TYPE="STUDY">Berber 2008</LINK>, <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK>, <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>, <LINK REF="STD-Reuter-2009" TYPE="STUDY">Reuter 2009</LINK>, <LINK REF="STD-Scaife-2003" TYPE="STUDY">Scaife 2003</LINK> and <LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK>. All of aforementioned studies with the addition of the <LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK>, <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK> and <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK> study do not define the possible confounders.</P>
<P>The effect modifiers are described only in the <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>, <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>, <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK> e <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK> study. In the study by <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK> there are not described the diagnostic criteria. With regard to item 8 (Data sources/ measurement) only the <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK> and <LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK> studies do not appropriately describes the source of the data. None of the 17 included studies shown the comparability  of the valuation methods of the two groups. None of the included study describes any efforts to address potential sources of bias (Item 9).</P>
<P>Only the <LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK> and <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK> explain  how the study size was arrived at (Item 10).  With regard to the Item 11 (Quantitative variables) only the studies by <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>, <LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK> e <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK> explain how quantitative variables were handled in the analyses. The statistical methods (Item 12) are exhaustively explained in all included studies, except in that of <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>.</P>
<P>Contrariwyse the methods used to control for confounding are described only in the <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK> study. No study explains how they were treated the missing data and only the studies by <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>, <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>, <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK> and <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK> describe the methods used to examine subgroups and interactions. The <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>, <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK> and <LINK REF="STD-Reuter-2009" TYPE="STUDY">Reuter 2009</LINK> studies are the only ones to explain how matching of cases and controls was addressed. No studies describe any sensitivity analysis carried out. With regard to Results sections (Item 13) (Participants) only the studies by <LINK REF="STD-Reuter-2009" TYPE="STUDY">Reuter 2009</LINK>  and <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK> report numbers of individuals at each stage of study and give reasons for non-participation at each stage.</P>
<P>Only the studies by <LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK> and <LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK> consider use of a flow diagram. With regard to Item 14 (Descriptive data) none of the studies, except the Gleisner study, give information on potential confounders and none of the studies indicate the number of participants with missing data for each variable of interest. With regard to Item 16 (Main results) we have found that only  the studies of <LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK>, <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>, <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>, <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK>, <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>, <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>, <LINK REF="STD-Reuter-2009" TYPE="STUDY">Reuter 2009</LINK>, <LINK REF="STD-Scaife-2003" TYPE="STUDY">Scaife 2003</LINK> e <LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK> give unadjusted estimates for the main results. Only in the studies of <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>, <LINK REF="STD-Reuter-2009" TYPE="STUDY">Reuter 2009</LINK> e <LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK> were reported the confounder-adjusted estimates and their precision. None of the studies report category boundaries when continuous variables were categorized and  translating estimates of relative risk into absolute risk for a meaningful time period. The <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>, <LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>, <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>, <LINK REF="STD-Kornprat-2007" TYPE="STUDY">Kornprat 2007</LINK>, <LINK REF="STD-Berber-2008" TYPE="STUDY">Berber 2008</LINK>, <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK> and <LINK REF="STD-Scaife-2003" TYPE="STUDY">Scaife 2003</LINK> studies do not are reported other analyses and sensitivity analyses (Item 17).</P>
<P>With regard to Discussion section in the item 18 we found that only the <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK> study do not  summarise key results with reference to study objectives. The studies by <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>, <LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>, <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>, <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK>, <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>, <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK>, <LINK REF="STD-Reuter-2009" TYPE="STUDY">Reuter 2009</LINK>, <LINK REF="STD-Scaife-2003" TYPE="STUDY">Scaife 2003</LINK> and <LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK> do not discuss limitations of the study, taking into account sources of potential bias or imprecision (Item 19).</P>
<P>The <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>, <LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>, <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>, <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK>, <LINK REF="STD-Reuter-2009" TYPE="STUDY">Reuter 2009</LINK> and <LINK REF="STD-Scaife-2003" TYPE="STUDY">Scaife 2003</LINK> studies do not give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence (Item 20). None of the studies give the source of funding and the role of the founders for the present study and, if applicable, for the original study on which the present article is based (Item 22).</P>
<P>In conclusion there were problems in important items in the STROBE (<LINK REF="REF-Vandenbroucke-2007" TYPE="REFERENCE">Vandenbroucke 2007</LINK>), for considering a studies of good quality.</P>
<P>
<B>RFA vs HR </B>
</P>
<P>All the studies were not randomised and this increases the potential for selection bias. In addition, there was imbalance in the baseline characteristics of the participants included in all studies. In a study (<LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>), all the patients in the RFA arm had contraindication to HR (extrahepatic disease, vessel contiguity and co-morbidity) and 17 patients in the control arm received CT. Similar imbalance between the group treatment were present In the other studies (<LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK>; <LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK>; <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>; <LINK REF="STD-Berber-2008" TYPE="STUDY">Berber 2008</LINK>; <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>; <LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK>, <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>, <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>). Otherwise in <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK> study's CRLMs, founded within the first year after colorectal resection, were underwent RFA; the HR was performed only in patients in whom RFA was not possible for number, diameter, or location of CRLMs.</P>
<P>The morbility was not reported in some studies (<LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK>; <LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK>: <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>; <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>) and the rate is reported in different modality in included studies: significant postoperative complication (<LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>), major complications (<LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>), complication rate (all) (<LINK REF="STD-Berber-2008" TYPE="STUDY">Berber 2008</LINK>), complications (major) (<LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK>), postoperative morbidity was graded according to Dindo classification system complications (<LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK>), complications (all) (<LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>), complication of any grade and major complications (<LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>). The authors (<LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>; <LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK>; <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>) don't report the definition of major complications.</P>
<P>
<B>RFA plus systemic CT versus systemic CT alone</B>
</P>
<P>At the present the information from this single RCT (<LINK REF="STD-Ruers-2010" TYPE="STUDY">Ruers 2010</LINK>) comes from an abstract of 2010 ASCO Annual Meeting where the adequacy of allocation concealment was not reported; however in original protocol allocation concealment was adequately reported (<LINK REF="REF-EORTC-40004-protocol" TYPE="REFERENCE">EORTC 40004 protocol</LINK>). The published baseline characteristics of the study and control group were well matched: patients with &#8804;9 unresectable CRC LM and no extrahepatic<SUP> </SUP>disease.</P>
<P>
<B>RFA plus adjuvant HAI versus RFA plus adjuvant HAI and HR</B>
</P>
<P>The study (<LINK REF="STD-Scaife-2003" TYPE="STUDY">Scaife 2003</LINK>) is a multicentric CCT and do not randomise the allocation of participants to the comparison groups increasing the potential for selection bias. The sample size was small (50 patients were identified in two hospitals) and there was a significant imbalance between the comparison groups in terms of gender and previous systemic chemotherapy.</P>
<P>
<B>RFA plus HR vs HR vs RFA alone vs systemic CT</B>
</P>
<P>The only observational study is highly exposed to selection bias(<LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>) . In this study the RFA was performed only when complete resection was not possible. However, other characteristics of both groups were apparently similar (gender, race, age 65 years at surgery; primary tumour factors: T classification, node status, colon vs. rectal location, recurrence-free interval 12 months; liver tumour factors: prehepatic resection CEA 200, number of tumours solitary tumour vs. 2 to 3 tumours vs. 3 tumours, size of largest tumour 5 cm).</P>
<P>
<B>RFA plus HR vs CSA plus HR</B>
</P>
<P>Selection bias is a primary threat to the only observational study (<LINK REF="STD-Kornprat-2007" TYPE="STUDY">Kornprat 2007</LINK>). The information on the main characteristic of the participants were limited. Outcomes in terms of DFS and OS were not described</P>
<P>
<B>RFA plus HR vs HR</B>
</P>
<P>The included studies (<LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>; <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK>; <LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK>) ware not randomised opening the potential threat of selection bias.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-03-21 13:29:37 +0100" MODIFIED_BY="[Empty name]">
<P>The most appropriate way of summarizing time-to-event data is to use methods of survival analysis and express the intervention effect as a hazard ratio. In the included studies these outcome are mostly reported as dichotomous data so we should have asked authors research data for each participant and perform an Individual patient data (IPD) meta-analysis. Given the study design and low quality of included studies we decided to give up and not to summarize these data.</P>
<P>Outcome data of individual studies are presented in the tables.</P>
<P>
<B>RFA versus HR</B>
</P>
<P>
<U>
<B>
<I>Overall survival</I>
</B>
</U>
</P>
<P>Thirteen studies comparing RFA with HR evaluated the overall survival (OS) of which two (<LINK REF="STD-Reuter-2009" TYPE="STUDY">Reuter 2009</LINK>; <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>) investigated the same participants in two subsequent periods of time (3 and 5 years respectively) . <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK> reported only the median OS that was 50.2 months for RFA and 112.7 months for patients undergoing HR with significant result (P=0.005) The characteristics of all trials included in this review are listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>Nine studies report the 3-years overall survival: <LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>, <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK>, <LINK REF="STD-Berber-2008" TYPE="STUDY">Berber 2008</LINK>, <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>, <LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK>, <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>, <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>, <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>, <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK>. In the 3-year OS studies 1632 patients were included: 452 undergoing to RFA and 1180 undergoing to HR.</P>
<P>Only seven studies report the 5-years overall survival: <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK>, <LINK REF="STD-Berber-2008" TYPE="STUDY">Berber 2008</LINK>, <LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK>, <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>, <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>, <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>, <LINK REF="STD-Reuter-2009" TYPE="STUDY">Reuter 2009</LINK>. In the 5-year OS studies 1373 cases were considered (454 undergoing to RFA and 919 undergoing to HR):</P>
<P>- <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK> 27% in RFA group (30 patients) vs 71% HR group (150 patients) (P &lt; 0.001)..</P>
<P>- <LINK REF="STD-Berber-2008" TYPE="STUDY">Berber 2008</LINK> 30% in RFA group (27 patients) vs 40% in HR group (30 patients) (P = 0.35).</P>
<P>- <LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK> 89.7% in RFA group (25 patients) vs 50.1% in HR group (42 patients) (P = 0.0263).</P>
<P>- <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK> 31.2% in RFA group (177 patients) vs 45.3% in HR group (278 patients) (P &#65308; 0.001).</P>
<P>- <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK> 38.5% in RFA group (37 patients) vs 65.7% in HR group (116 patients) (P = 0.227).</P>
<P>- <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK> 48% in RFA group (28 patients) vs 51% in HR group (82 patients) (P = 0.930).</P>
<P>- <LINK REF="STD-Reuter-2009" TYPE="STUDY">Reuter 2009</LINK> 49% in RFA group (66 patients) vs 45% in HR group (126 patients) (P = 0.31).</P>
<P>
<U>
<B>
<I>Disease Free Survival </I>
</B>
</U>
</P>
<P>Only seven studies report the DFS <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>
<LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK> reported a 5-year DFS rate of 0% in patients treated with RFA vs. 50% in the group treated with HR (P=0.01). In the <LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK> study the 5 year DFS was 15% in patients treated with RFA vs 17% following HR (P=0.06). <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK> reported only the median survival that was 42.6 months for RFA and 55.2 months for patients undergoing HR with non-significant result (P = 0.07). <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK> reported a lower DFS in RFA group without significant result (P = 0.247). <LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK> reported the 3 year DFS: 7.4% in RFA group vs 39.8% in HR group. <LINK REF="STD-Berber-2008" TYPE="STUDY">Berber 2008</LINK> reported only patients without extra-hepatic disease and the median DFS was 9 months for the RFA group and 30 months for HR (P &lt; 0.0001). In <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK> DFS rates did not differ between patients who underwent RFA and HR (P 0.98): in the 226 patients with a single metastatic tumour &#65308;3 cm 5-year DFS rates were 33.6% in the RFA group and 31.6% in the HR group. In the patients with solitary metastatic tumour &#8805;3 cm 5-years DFS rates were significantly lower in the RFA group (23.1% vs 36.6%; P = 0.01). RFA rates was lower in patients with multiple liver metastases (6.4% in the RFA group vs 16.2% in HR group).</P>
<P>
<U>
<B>
<I>Post-operative mortality </I>
</B>
</U>
</P>
<P>Post-operative mortality has a very low rate: 1/464 in RFA group and 4/845 in HR group. Only <LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK> reported one postoperative death in RFA group. In HR group <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK> and <LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK> reported respectively only one postoperative death; <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK> reported 2 postoperative deaths.</P>
<P>
<U>
<B>Local Recurrence</B>
</U>
</P>
<P>Two types of local recurrence were distinguished: marginal recurrence (tumour growth at the site of HR or RFA) and intrahepatic recurrence (tumour growth at a site different from the previous treatment localization).</P>
<UL>
<LI>
<B>
<I>Marginal recurrence</I>
</B>
</LI>
</UL>
<P>The marginal recurrence was higher in the RFA group vs HR group, respectively: 11/30 vs 8/150 (P = 0.001) <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK>, 8/25 vs 6/42 (P = 0.85) <LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK>, 3/28 vs 2/82 (P &lt; 0.001) <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>, 7/30 vs 1/59 (P &lt; 0.01) <LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK>, 5/46 vs 2/95 <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>, 8/22 vs 0/30 <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>.</P>
<UL>
<LI>
<B>
<I>Intrahepatic recurrence</I>
</B>
</LI>
</UL>
<P>The intrahepatic recurrence was higher in the RFA group vs HR group, respectively: 5/30 vs 27/150 <LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK>, 8/25 vs 6/42 <LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK>, 13/30 vs 10/59 <LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK>, 11/46 vs 10/95 (P=0.026) <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>, 1/22 vs 8/30 <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>.</P>
<UL>
<LI>
<B>
<I>Marginal recurrence with intrahepatic recurrence</I>
</B>
</LI>
</UL>
<P>Only three studies reported the combination of marginal recurrence with intrahepatic recurrence; the recurrence was higher in the RFA group vs HR group, respectively: 3/37 vs 8/116 <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>, 1/28 vs 0/82 <LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>, 2/22 vs 1/30 <LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>.</P>
<P>The two other outcomes were not evaluated because data were not arranged in the included studies: treatment efficacy (proportion of patient with residual disease following treatment) and procedure related complications/adverse events</P>
<P>
<B>RFA systemic plus CT versus systemic CT alone</B>
</P>
<P>In the Ruers study 119 patients were randomised to RFA plus systemic CT or CT alone as first line therapy for metastatic colorectal cancer (<LINK REF="STD-Ruers-2010" TYPE="STUDY">Ruers 2010</LINK>). The median progression free survival was 16.8 months in the RFA + CT<SUP> </SUP>group (95% CI, 11.7-22.1) and 9.9 months (9.3- 13.7) in the CT<SUP> </SUP>group (P = 0.025). Overall survival (30-months) was 61.7% (95% CI, 48.21-73.93)<SUP> </SUP>in the RFA + CT group and 57.6% (44.07-70.39) in the CT group.<SUP> </SUP>In eligible patients (RFA + CT; 57 pts, CT; 58 pts) these rates<SUP> </SUP>were 64.9% (95% CI, 51.13-77.09) and 56.9% (43.23-69.84),<SUP> </SUP>respectively. The benefit of RFA in combination with CT were present in this study, however limited conclusions can be made due to smaller follow-up (30-months) <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
<P>
<B>RFA plus HAI versus RFA plus adjuvant HAI and HR</B>
</P>
<P>One study compared RFA with HAI or RFA, adjuvant HAI, and surgical resection alone as first line therapy for metastatic colorectal cancer in 50 patients (<LINK REF="STD-Scaife-2003" TYPE="STUDY">Scaife 2003</LINK>). There was no evidence of disease In 26% (5/19) of patients underwent RFA with HAI and in 35% (11/31) of patients underwent RFA with surgical resection and HAI. Overall survival was 73% (14/19) in RFA with HAI group and 61% (19/31) in patients underwent RFA with surgical resection and HAI. There are no conclusions to draw from this limited research due to the small numbers of patients in this study and the smaller follow-up <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
<P>
<B>RFA plus HR vs HR vs RFA alone vs chemiotherapy</B>
</P>
<P>In 190 patients underwent HR there are the best survival (3-year survival 73%, 4-year 65%, 5-year 58%, P 0.0001). RFA (57 pts.) showed a higher incidence of local recurrence: 84% in RFA only, 63% in RHA + HR, 52% in HR. The survival rate was similar in RFA + hepatic resection (101 pts.) and RFA groups (3 years survival 43% vs. 37%, 4-years 36% vs. 22%, P not significant). The poor results in patients underwent RFA was a consequence of the more advanced stage (&#8220;unresectable&#8221; CR LM). In RFA resection or RFA the survival was better than after chemotherapy alone (70 pts.) (P 0.0017) (<LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>) <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>.</P>
<P>
<B>RFA with HR vs CSA plus HR</B>
</P>
<P>The use of intraoperative RFA was associated with a lower blood loss (median 500 ml vs 200 ml). The incidence of postoperative complications ablation technique related was higher in patients underwent CSA. In CSA group 3 patients developed a hepatic abscess resolved after percutaneous drainage; in RFA group there was not present complications ablation technique related. The local recurrence was similar in both groups: 14% in the RFA arm and 12% in the CSA arm (<LINK REF="STD-Kornprat-2007" TYPE="STUDY">Kornprat 2007</LINK>) <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>.</P>
<P>
<B>RFA vs HR plus RFA</B>
</P>
<P>Four studies (<LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>, <LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK>, <LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>) comparing RFA with HR evaluated the overall survival (OS). In McKay's trial the median survival for RFA and resection in combination with RFA was 2.6 years (95% CI = 1.8 to 3.3 years) vs 2.3 (95% CI = 1.6 to 3.2 years), respectively (<LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK>).</P>
<P>
<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-03-21 13:29:57 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review gathers informations mainly from observational studies which are vulnerable to different types of bias. The imbalance between characteristics of patients in the allocated groups appears to be the main concern. Only one randomised clinical trial (published as an abstract), that compared 60 pts. underwent RFA plus CT vs 59 underwent CT alone, was found. This study showed that DFS was significantly higher in the group that received RFA. However, it was not able to provide information on overall survival. In conclusion, evidence from the included studies are insufficient to recommend RFA for a radical oncological treatment of CRLMs.These conclusions are in agreement with reviews of <LINK REF="REF-de-Jong-2011" TYPE="REFERENCE">de Jong 2011</LINK> and <LINK REF="REF-Hompes-2011" TYPE="REFERENCE">Hompes 2011</LINK>. However, it must be noted that recruitment of patients is difficult (<LINK REF="REF-Bauditz-2011" TYPE="REFERENCE">Bauditz 2011</LINK>). For the same reason a French RCT (essai FFCD 2002-02) failed because too few centres agreed to participate (<LINK REF="REF-Benoist-2004" TYPE="REFERENCE">Benoist 2004</LINK>). In most papers currently available in the literature the patients undergoing RFA are unresectable and have a worse clinicopathologic characteristics than resectable patients undergoing HR (extrahepatic disease, higher tumour burden evidenced by higher CEA levels, more co-morbidities and type of RFA). The analysis of these results is "very difficult and dangerous" (<LINK REF="REF-Hompes-2011" TYPE="REFERENCE">Hompes 2011</LINK>) and comparing "apples with oranges" (<LINK REF="REF-Tsai-2009" TYPE="REFERENCE">Tsai 2009</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-01-05 21:56:00 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-08-19 23:36:07 +0200" MODIFIED_BY="[Empty name]">
<P>The confusion regarding interventions, comparisons and outcomes rendered the data unusable and unsuitable for drawing conclusions. There is insufficient evidence however to recommend its use of RFA for a radical treatment of CLRLMs. Now the RFA, associated with CT and/or surgery, has only a adjuvant role.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-01-05 21:56:00 +0100" MODIFIED_BY="[Empty name]">
<P>Future comparisons of HR versus RFA are needed:</P>
<P>- the first tier of future research studies are studies assessing the comparative effectiveness of RFA vs. HR for palliative treatment of CRLMs;</P>
<P>- the second tier of future research pertains to studying the patients with RFA vs HR as the first-line treatment in oncological radical treatment of CRLMs;</P>
<P>- the third tier of future research studies are studies assessing the comparative effectiveness of RFA systemic plus CT versus systemic CT alone for palliative treatment of CRLMs.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-07-22 11:08:06 +0200" MODIFIED_BY="[Empty name]">
<P>None</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-08-16 13:26:55 +0200" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-03-21 13:24:28 +0100" MODIFIED_BY="[Empty name]">
<P>Dr. Iosief Abraha<BR/>Evaluation of methodological quality of trials<BR/>Data collection<BR/>Writing the text of review</P>
<P>Dr. Carlo Boselli<BR/>Evaluation of methodological quality of trials<BR/>Data collection<BR/>Revision of the review</P>
<P>Dr. Davide Cavaliere<BR/>Literature search and identification of trials<BR/>Data collection<BR/>Verification of data and entry in Revman<BR/>
</P>
<P>Dr. Roberto Cirocchi<BR/>Literature search and identification of trials<BR/>Data collection<BR/>Writing the text of review</P>
<P>Dr Alessandro Montedori<BR/>Literature search and identification of trials<BR/>Evaluation of methodological quality of trials<BR/>Revision of the review</P>
<P>Prof. Giuseppe Noya<BR/>Literature search and identification of trials<BR/>Evaluation of methodological quality of trials<BR/>Writing the text of review</P>
<P>Dr Amilcare Parisi<BR/>Literature search and identification of trials<BR/>Data collection</P>
<P>Dr. Stefano Trastulli<BR/>Evaluation of methodological quality of trials<BR/>Data collection<BR/>Revision of the review<BR/>
<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2010-08-24 15:19:51 +0200" MODIFIED_BY="[Empty name]">
<P>This is a substantially updated version of a protocol originally proposed by AC Wei et al., first published in the Cochrane Library 2007 issue 1.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-05-09 11:17:37 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-05-09 11:17:37 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-05-09 11:07:15 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdalla-2004" MODIFIED="2012-04-27 17:31:15 +0200" MODIFIED_BY="[Empty name]" NAME="Abdalla 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-04-27 17:31:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al.</AU>
<TI>Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases</TI>
<SO>Annals of Surgery</SO>
<YR>2004</YR>
<VL>239</VL>
<PG>825-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aloia-2006" MODIFIED="2012-04-27 17:31:33 +0200" MODIFIED_BY="[Empty name]" NAME="Aloia 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-04-27 17:31:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al.</AU>
<TI>Solitary colorectal liver metastasis. Resection determines outcome</TI>
<SO>Archives of Surgery</SO>
<YR>2006</YR>
<VL>141</VL>
<PG>460-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berber-2008" MODIFIED="2012-04-27 17:30:06 +0200" MODIFIED_BY="[Empty name]" NAME="Berber 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-04-27 17:30:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berber E, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE</AU>
<TI>Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2008</YR>
<VL>12</VL>
<PG>1976-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gleisner-2008" MODIFIED="2012-04-27 17:35:24 +0200" MODIFIED_BY="[Empty name]" NAME="Gleisner 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-04-27 17:35:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gleisner AL, Choti MA, Assumpcao L, Nathan H, Schulick RD, Pawlik TM</AU>
<TI>Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation.</TI>
<SO>Archives of Surgery</SO>
<YR>2008</YR>
<VL>143</VL>
<PG>1204-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hur-2009" MODIFIED="2012-04-27 17:36:19 +0200" MODIFIED_BY="[Empty name]" NAME="Hur 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-27 17:36:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hur H, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, et al.</AU>
<TI>Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases</TI>
<SO>America Journal of Surgery</SO>
<YR>2009</YR>
<VL>197</VL>
<PG>728-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2011" MODIFIED="2012-04-27 17:50:28 +0200" MODIFIED_BY="[Empty name]" NAME="Kim 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-04-27 17:50:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim KH, Yoon YS, Yu CS, Kim TW, Kim HJ, Kim PN, et al.</AU>
<TI>Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases</TI>
<SO>Journal of Korean Surgical Society</SO>
<YR>2011</YR>
<VL>81</VL>
<PG>25-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kornprat-2007" MODIFIED="2012-04-27 17:51:28 +0200" MODIFIED_BY="[Empty name]" NAME="Kornprat 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-27 17:51:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornprat P, Jarnagin WR, DeMatteo RP, Fong Y, Blumgart LH, D'Angelica M</AU>
<TI>Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer</TI>
<SO>Archives of Surgery</SO>
<YR>2007</YR>
<VL>142</VL>
<PG>1087-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2008" MODIFIED="2012-04-27 17:55:29 +0200" MODIFIED_BY="[Empty name]" NAME="Lee 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-04-27 17:55:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee WS, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, et al.</AU>
<TI>Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2008</YR>
<VL>42</VL>
<PG>945-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKay-2009" MODIFIED="2012-04-27 17:56:15 +0200" MODIFIED_BY="[Empty name]" NAME="McKay 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-27 17:56:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKay A, Fradette K, Lipschitz J</AU>
<TI>Long-term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases</TI>
<SO>HPB Surgery</SO>
<YR>2009</YR>
<VL>2009:346863.</VL>
<PG>Epub 2010 Feb 1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oshowo-2003" MODIFIED="2012-04-27 18:01:47 +0200" MODIFIED_BY="[Empty name]" NAME="Oshowo 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-04-27 18:01:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I</AU>
<TI>Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases</TI>
<SO>British Journal of Surgery</SO>
<YR>2003</YR>
<VL>90</VL>
<PG>1240-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otto-2010" MODIFIED="2012-04-27 18:02:44 +0200" MODIFIED_BY="[Empty name]" NAME="Otto 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-27 18:02:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otto G, Duber C, Hoppe-Lotichius M, Konig J, Heise M, Pitton MB</AU>
<TI>Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery</TI>
<SO>Annals of Surgery</SO>
<YR>2010</YR>
<VL>251</VL>
<PG>796-803</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-2008" MODIFIED="2012-04-27 18:03:19 +0200" MODIFIED_BY="[Empty name]" NAME="Park 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-04-27 18:03:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park IJ, Kim HC, Yu CS, Kim PN, Won HJ, Kim JC</AU>
<TI>Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>227-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reuter-2009" MODIFIED="2012-05-09 11:06:36 +0200" MODIFIED_BY="[Empty name]" NAME="Reuter 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-09 11:06:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reuter NP, Woodall CE, Scoggins CR, McMasters KM, Martin RCG</AU>
<TI>Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent?</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2009</YR>
<VL>13</VL>
<PG>486-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruers-2010" MODIFIED="2012-04-27 18:05:23 +0200" MODIFIED_BY="[Empty name]" NAME="Ruers 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-27 18:05:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruers T, Punt CJ, van Coevorden F, Borel Rinkes I, Ledermann JA, Poston GJ, et al.</AU>
<TI>Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>15s:suppl</NO>
<PG>abstr 3526</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scaife-2003" MODIFIED="2012-04-27 18:06:15 +0200" MODIFIED_BY="[Empty name]" NAME="Scaife 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-04-27 18:06:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scaife CL, Curley SA, Izzo F, Marra P, Delrio P, Daniele B, et al.</AU>
<TI>Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>348-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiffman-2010" MODIFIED="2012-04-27 18:07:09 +0200" MODIFIED_BY="[Empty name]" NAME="Schiffman 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-27 18:07:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffman SC, Bower M, Brown RE, Martin RC, McMasters KM, Scoggins CR</AU>
<TI>Hepatectomy is superior to thermal ablation for patients with a solitary colorectal liver metastasis</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2010</YR>
<VL>14</VL>
<PG>1881-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vyslouzil-2009" MODIFIED="2012-04-27 18:07:53 +0200" MODIFIED_BY="[Empty name]" NAME="Vyslouzil 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-27 18:07:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vyslouzil K, Klementa I, Starý L, Zboril P, Skalický P, Dlouhý M, et al.</AU>
<TI>Radiofrequency ablation of colorectal liver metastases</TI>
<SO>Zentralbl Chir</SO>
<YR>2009</YR>
<VL>134</VL>
<PG>145-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-2007" MODIFIED="2012-05-09 11:07:15 +0200" MODIFIED_BY="[Empty name]" NAME="White 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-05-09 11:07:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White RR, Avital I, Sofocleous CT, Brown KT, Brody LA, Covey A, et al.</AU>
<TI>Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2007</YR>
<VL>11</VL>
<PG>256-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-05-09 11:17:37 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Asfoor-2008" MODIFIED="2012-05-09 11:17:37 +0200" MODIFIED_BY="[Empty name]" NAME="Al-Asfoor 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-05-09 11:17:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Al-Asfoor A, Fedorowicz Z</AU>
<TI>Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<PG>CD006039</PG>
<IDENTIFIERS MODIFIED="2012-05-09 11:17:36 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-09 11:17:36 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006039.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Curley-2008" MODIFIED="2012-04-27 20:25:37 +0200" MODIFIED_BY="[Empty name]" NAME="Curley 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-04-27 20:25:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curley S A</AU>
<TI>Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>11-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Jong-2009" MODIFIED="2012-04-27 20:26:57 +0200" MODIFIED_BY="[Empty name]" NAME="de Jong 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-27 20:26:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, et al.</AU>
<TI>Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients</TI>
<SO>Annals of Surgery</SO>
<YR>2009</YR>
<VL>250</VL>
<PG>440-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doyle-2010" MODIFIED="2012-04-27 20:28:37 +0200" MODIFIED_BY="[Empty name]" NAME="Doyle 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-27 20:28:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doyle MB, Chapman WC</AU>
<TI>Radiofrequency ablation for resectable colorectal hepatic metastases: is it time for a randomized controlled trial?</TI>
<SO>Annals of Surgery</SO>
<YR>2010</YR>
<VL>251</VL>
<PG>803-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elias-2004" MODIFIED="2012-04-27 20:29:15 +0200" MODIFIED_BY="[Empty name]" NAME="Elias 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-04-27 20:29:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elias D, Baton O, Sideris L, Matsuhisa T, Pocard M, Lasser P</AU>
<TI>Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2004</YR>
<VL>11</VL>
<PG>500-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frich-2008a" MODIFIED="2012-04-27 20:29:59 +0200" MODIFIED_BY="[Empty name]" NAME="Frich 2008a" YEAR="2008">
<REFERENCE MODIFIED="2012-04-27 20:29:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frich L</AU>
<TI>Local ablation of colorectal liver metastases - a systematic review</TI>
<SO>Tidsskr Nor Laegeforen</SO>
<YR>2008</YR>
<VL>128</VL>
<PG>54-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frich-2008b" MODIFIED="2012-04-27 20:29:52 +0200" MODIFIED_BY="[Empty name]" NAME="Frich 2008b" YEAR="">
<REFERENCE MODIFIED="2012-04-27 20:29:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frich L, Brabrand K, Aalokken TM, Edwin B, Gladhaug IP</AU>
<TI>Radiofrequency ablation of colorectal liver metastases</TI>
<SO>Tidsskr Nor Laegeforen</SO>
<YR>2008</YR>
<VL>128</VL>
<PG>57-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grundmann-2007" MODIFIED="2012-04-27 20:31:11 +0200" MODIFIED_BY="[Empty name]" NAME="Grundmann 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-27 20:31:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grundmann RT</AU>
<TI>Liver metastases of colorectal carcinoma--may the DRG-system influence the operative procedure?</TI>
<SO>Zentralblatt fur Chirurgie</SO>
<YR>2007</YR>
<VL>132</VL>
<PG>287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jansen-2008" MODIFIED="2012-04-27 20:32:18 +0200" MODIFIED_BY="[Empty name]" NAME="Jansen 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-04-27 20:32:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jansen MC, van Wanrooy S, van Hillegersberg R, Rijken AM, van Coevorden F, Prevoo W, et al.</AU>
<TI>Assessment of systemic inflammatory response (SIR) in patients undergoing radiofrequency ablation or partial liver resection for liver tumors</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2008</YR>
<VL>34</VL>
<PG>662-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joosten-2005" MODIFIED="2012-04-27 20:32:51 +0200" MODIFIED_BY="[Empty name]" NAME="Joosten 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-04-27 20:32:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joosten J, Jager G, Oyen W, Wobbes T, Ruers T</AU>
<TI>Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>1152-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leblanc-2008" MODIFIED="2012-04-27 20:33:06 +0200" MODIFIED_BY="[Empty name]" NAME="Leblanc 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-04-27 20:33:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leblanc F, Fonck M, Brunet R, Becouarn Y, Mathoulin-Pelissier S, Evrard S</AU>
<TI>Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2008</YR>
<VL>34</VL>
<PG>185-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leen-2007" MODIFIED="2012-04-27 20:33:30 +0200" MODIFIED_BY="[Empty name]" NAME="Leen 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-27 20:33:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leen E, Horgan PG</AU>
<TI>Radiofrequency ablation of colorectal liver metastases</TI>
<SO>Surgical Oncology</SO>
<YR>2007</YR>
<VL>16</VL>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lupo-2007" MODIFIED="2012-04-27 20:33:55 +0200" MODIFIED_BY="[Empty name]" NAME="Lupo 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-27 20:33:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lupo L, Gallerani A, Panzera P, Tandoi F, Di Palma G, Memeo V</AU>
<TI>Randomized clinical trial of radiofrequency-assisted versus clamp-crushing liver resection</TI>
<SO>British Journal of Surgery</SO>
<YR>2007</YR>
<VL>94</VL>
<PG>287-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-2006" MODIFIED="2012-04-27 20:38:27 +0200" MODIFIED_BY="[Empty name]" NAME="Martin 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-04-27 20:38:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin RC, Scoggins CR, McMasters KM</AU>
<TI>A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy</TI>
<SO>Journal of Surgical Oncology</SO>
<YR>2006</YR>
<VL>93</VL>
<PG>387-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulier-2008" MODIFIED="2012-04-27 20:39:21 +0200" MODIFIED_BY="[Empty name]" NAME="Mulier 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-04-27 20:39:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T</AU>
<TI>Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>144-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pawlik-2003" MODIFIED="2012-04-27 20:39:50 +0200" MODIFIED_BY="[Empty name]" NAME="Pawlik 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-04-27 20:39:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA</AU>
<TI>Combined Resection and Radiofrequency Ablation for AdvancedHepatic Malignancies: Results in 172 Patients</TI>
<SO>Annals of Surgical Oncolology</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>1059-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reurs-2007" MODIFIED="2012-04-27 20:42:33 +0200" MODIFIED_BY="[Empty name]" NAME="Reurs 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-27 20:42:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruers TJ, Joosten JJ, Wiering B, Langenhoff BS, Dekker HM, Wobbes T, Oyen WJ, et al.</AU>
<TI>Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2007</YR>
<VL>14</VL>
<PG>1161-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scott-2001" MODIFIED="2012-04-27 20:40:50 +0200" MODIFIED_BY="[Empty name]" NAME="Scott 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-04-27 20:40:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scott DJ, Young WN, Watumull LM, Lindberg G, Fleming JB, Huth JF, et al.</AU>
<TI>Accuracy and effectiveness of laparoscopic vs open hepatic radiofrequency ablation</TI>
<SO>Surgical Endoscopy</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>135-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stang-2009" MODIFIED="2012-04-27 20:43:10 +0200" MODIFIED_BY="[Empty name]" NAME="Stang 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-27 20:43:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D</AU>
<TI>A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases</TI>
<SO>European Journal of Cancer</SO>
<YR>2009</YR>
<VL>45</VL>
<PG>1748-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutherland-2006" MODIFIED="2012-04-27 20:43:34 +0200" MODIFIED_BY="[Empty name]" NAME="Sutherland 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-04-27 20:43:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ</AU>
<TI>Radiofrequency ablation of liver tumors: a systematic review</TI>
<SO>Archives of Surgery</SO>
<YR>2006</YR>
<VL>141</VL>
<PG>181-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tez-2009" MODIFIED="2012-04-27 20:44:02 +0200" MODIFIED_BY="[Empty name]" NAME="Tez 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-27 20:44:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tez M, Tez S</AU>
<TI>Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?</TI>
<SO>Annals of Surgical Oncolology</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>1804</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2010" MODIFIED="2012-04-27 20:44:51 +0200" MODIFIED_BY="[Empty name]" NAME="Wong 2010" YEAR="2009">
<REFERENCE MODIFIED="2012-04-27 20:44:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, et al.</AU>
<TI>2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<PG>493-508</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2011-08-20 07:45:10 +0200" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-05-08 12:15:25 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-05-08 12:15:25 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adam-2004" MODIFIED="2012-04-27 20:45:23 +0200" MODIFIED_BY="[Empty name]" NAME="Adam 2004" TYPE="JOURNAL_ARTICLE">
<AU>Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al.</AU>
<TI>Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival</TI>
<SO>Annals of Surgery</SO>
<YR>2004</YR>
<VL>240</VL>
<PG>644-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adam-2009" MODIFIED="2012-04-27 20:45:53 +0200" MODIFIED_BY="[Empty name]" NAME="Adam 2009" TYPE="JOURNAL_ARTICLE">
<AU>Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, et al.</AU>
<TI>Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<PG>1829-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-American-Cancer-Society-2010" MODIFIED="2010-08-04 20:21:09 +0200" MODIFIED_BY="[Empty name]" NAME="American Cancer Society 2010" TYPE="OTHER">
<AU>American Cancer Society</AU>
<TI>Cancer Facts and Figures 2010</TI>
<SO>http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bauditz-2011" MODIFIED="2012-05-08 12:15:25 +0200" MODIFIED_BY="[Empty name]" NAME="Bauditz 2011" TYPE="JOURNAL_ARTICLE">
<AU>Bauditz J</AU>
<TI>Radiofrequency ablation for treatment of metastatic colorectal carcinoma: state of the art despite of missing randomized trials?</TI>
<SO>Zeitschrift für Gastroenterologie</SO>
<YR>2011</YR>
<VL>11</VL>
<PG>624-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benoist-2004" MODIFIED="2012-04-27 21:03:26 +0200" MODIFIED_BY="[Empty name]" NAME="Benoist 2004" TYPE="JOURNAL_ARTICLE">
<AU>Benoist S, Nordlinger B</AU>
<TI>Radiofrequency ablation in liver tumours</TI>
<SO>Annals of Oncology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Suppl 4</NO>
<PG>313&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boutros-2010" MODIFIED="2012-04-27 21:03:57 +0200" MODIFIED_BY="[Empty name]" NAME="Boutros 2010" TYPE="JOURNAL_ARTICLE">
<AU>Boutros C, Somasundar P, Garrean S, Saied A, Espat NJ</AU>
<TI>Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis</TI>
<SO>Surgical Oncolology</SO>
<YR>2010</YR>
<VL>19</VL>
<PG>e22-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Jong-2011" MODIFIED="2012-04-27 21:11:35 +0200" MODIFIED_BY="[Empty name]" NAME="de Jong 2011" TYPE="JOURNAL_ARTICLE">
<AU>de Jong MC, Mayo SC, Pawlik TM</AU>
<TI>Outcomes of ablation versus resection for colorectal liver metastases</TI>
<SO>Annals of Gastroenterology &amp; Hepatology</SO>
<YR>2010</YR>
<VL>252</VL>
<PG>142-8.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Decadt-2004" MODIFIED="2012-04-27 21:10:27 +0200" MODIFIED_BY="[Empty name]" NAME="Decadt 2004" TYPE="JOURNAL_ARTICLE">
<AU>Decadt B, Siriwardena AK</AU>
<TI>Radiofrequency ablation of liver tumours: systematic review</TI>
<SO>Lancet Oncology</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>9</NO>
<PG>550-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2001" MODIFIED="2012-04-27 21:10:21 +0200" MODIFIED_BY="[Empty name]" NAME="Egger 2001" TYPE="BOOK">
<AU>Egger M, Smith GD, Altman DG</AU>
<SO>Systematic reviews in health care: meta-analysis in context</SO>
<YR>2001</YR>
<PB>BMJ Publishing</PB>
<CY>Cornwall, England</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EORTC-40004-protocol" MODIFIED="2011-09-01 14:05:26 +0200" MODIFIED_BY="[Empty name]" NAME="EORTC 40004 protocol" TYPE="OTHER">
<AU>Ruers T, Mauer M, Lentz MA</AU>
<TI>CLOCC trial (Chemotherapy + Local ablation versus Chemotherapy). Randomized phase II study investigating the role of local treatment of liver metastases by radiofrequency combined with chemotherapy and of chemotherapy alone in patients with unresectable colorectal liver metastases</TI>
<SO>http://www.eortc.be/protoc/details.asp?protocol=40004</SO>
<YR>(accessed 1 September 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erce-2003" MODIFIED="2012-04-27 21:04:38 +0200" MODIFIED_BY="[Empty name]" NAME="Erce 2003" TYPE="JOURNAL_ARTICLE">
<AU>Erce C, Parks RW</AU>
<TI>Interstitial ablative techniques for hepatic tumours</TI>
<SO>British Journal of Surgery</SO>
<YR>2003</YR>
<VL>90</VL>
<PG>272-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feliberti-2006" MODIFIED="2010-08-05 07:59:03 +0200" MODIFIED_BY="[Empty name]" NAME="Feliberti 2006" TYPE="JOURNAL_ARTICLE">
<AU>Feliberti EC, Wagman LD</AU>
<TI>Radiofrequency ablation of liver metastases from colorectal carcinoma</TI>
<SO>Cancer Control</SO>
<YR>2006</YR>
<VL>13</VL>
<PG>48-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcea-2003" MODIFIED="2012-04-27 21:04:52 +0200" MODIFIED_BY="[Empty name]" NAME="Garcea 2003" TYPE="JOURNAL_ARTICLE">
<AU>Garcea G, Lloyd TD, Aylott C, Maddern G, Berry DP</AU>
<TI>The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours</TI>
<SO>European Journal of Cancer</SO>
<YR>2003</YR>
<VL>39</VL>
<PG>2150-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garden-2006" MODIFIED="2010-08-04 22:02:01 +0200" MODIFIED_BY="[Empty name]" NAME="Garden 2006" TYPE="JOURNAL_ARTICLE">
<AU>Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW</AU>
<TI>Guidelines for resection of colorectal cancer liver metastases</TI>
<SO>Gut</SO>
<YR>2006</YR>
<VL>55</VL>
<PG>Suppl 3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gillams-2004" MODIFIED="2012-04-27 21:08:18 +0200" MODIFIED_BY="[Empty name]" NAME="Gillams 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gillams AR, Lees WR</AU>
<TI>Radio-frequency ablation of colorectal liver metastases in 167 patients</TI>
<SO>European Radiolology</SO>
<YR>2004</YR>
<VL>14</VL>
<PG>2261-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gillams-2008" MODIFIED="2012-04-27 21:08:08 +0200" MODIFIED_BY="[Empty name]" NAME="Gillams 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gillams AR, Lees WR</AU>
<TI>Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>2008</YR>
<VL>19</VL>
<PG>712-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldberg-1998" MODIFIED="2012-04-27 21:06:24 +0200" MODIFIED_BY="[Empty name]" NAME="Goldberg 1998" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg SN, Hahn PF, Tanabe KK, Mueller PR, Schima W, Athanasoulis CA, et al.</AU>
<TI>Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis?</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>101-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goode-2005" MODIFIED="2012-04-27 21:12:16 +0200" MODIFIED_BY="[Empty name]" NAME="Goode 2005" TYPE="BOOK_SECTION">
<AU>Goode JA, Sabharwal T, Adam A</AU>
<TI>Percutaneous ablation of hepatic metastases</TI>
<SO>Focal liver lesions</SO>
<YR>2005</YR>
<PG>337-48</PG>
<ED>Lencioni R, Cioni D, Bartolozzi C</ED>
<PB>Springer-Verlag</PB>
<CY>Heidelberg</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gray-2001" MODIFIED="2012-04-27 21:07:52 +0200" MODIFIED_BY="[Empty name]" NAME="Gray 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al.</AU>
<TI>Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer</TI>
<SO>Annals of Oncology</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>1711-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hompes-2011" MODIFIED="2011-08-19 23:52:01 +0200" MODIFIED_BY="[Empty name]" NAME="Hompes 2011" TYPE="JOURNAL_ARTICLE">
<AU>Hompes D, Prevoob Aw, Ruersa T</AU>
<TI>Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin</TI>
<SO>Cancer Imaging</SO>
<YR>2011</YR>
<VL>11</VL>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Idelevich-2009" MODIFIED="2010-08-05 07:50:38 +0200" MODIFIED_BY="[Empty name]" NAME="Idelevich 2009" TYPE="JOURNAL_ARTICLE">
<AU>Idelevich E, Greif F, Mavor E, Miller R, Kashtan H, Susmalian S, Ariche A, Brenner B, Baruch NB, Dinerman M, Shani A</AU>
<TI>Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer</TI>
<SO>Chemotherapy</SO>
<YR>2009</YR>
<VL>55</VL>
<PG>76-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knudsen-2009" MODIFIED="2012-04-27 21:08:56 +0200" MODIFIED_BY="[Empty name]" NAME="Knudsen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Knudsen AR, Kannerup AS, Mortensen FV, Nielsen DT</AU>
<TI>Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy</TI>
<SO>Acta Radiologica</SO>
<YR>2009</YR>
<VL>50</VL>
<PG>716-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lau-2003" MODIFIED="2012-04-27 21:09:23 +0200" MODIFIED_BY="[Empty name]" NAME="Lau 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lau TN, Lo RHG, Tan BS</AU>
<TI>Colorectal hepatic metastases: role of radiofrequency ablation</TI>
<SO>Annals of the Academy of Medicine, Singapore</SO>
<YR>2003</YR>
<VL>32</VL>
<PG>212-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lencioni-2004" MODIFIED="2012-04-27 21:09:44 +0200" MODIFIED_BY="[Empty name]" NAME="Lencioni 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lencioni R, Crocetti L, Cioni D, Della Pina C, Bartolozzi C</AU>
<TI>Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises</TI>
<SO>Investigative Radiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>689-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lencioni-2005" MODIFIED="2012-04-27 21:12:49 +0200" MODIFIED_BY="[Empty name]" NAME="Lencioni 2005" TYPE="BOOK_SECTION">
<AU>Lencioni R, Cioni D, Lera J, Rocchi E, Della Pina C, Crocetti L</AU>
<TI>Radiofrequency ablation: principles and techniques</TI>
<SO>Focal liver lesions</SO>
<YR>2005</YR>
<PG>307-316</PG>
<ED>Lencioni R, Cioni D, Bartolozzi C</ED>
<PB>Springer-Verlag</PB>
<CY>Heidelberg (Germany)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lencioni-2009" MODIFIED="2012-04-27 21:13:25 +0200" MODIFIED_BY="[Empty name]" NAME="Lencioni 2009" TYPE="BOOK_SECTION">
<AU>Lencioni R, Crocetti L, Cioni D</AU>
<TI>Loco-regional ablative therapies for colorectal metastases</TI>
<SO>Recent advances in liver surgery</SO>
<YR>2009</YR>
<PG>234-41</PG>
<ED>Dionigi R</ED>
<PB>Landes Bioscience</PB>
<CY>Austin (USA)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Machi-2006" MODIFIED="2012-04-27 21:14:03 +0200" MODIFIED_BY="[Empty name]" NAME="Machi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, et al.</AU>
<TI>Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management</TI>
<SO>Cancer Journal</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>318&#8211;26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGahan-1996" MODIFIED="2012-04-27 21:14:47 +0200" MODIFIED_BY="[Empty name]" NAME="McGahan 1996" TYPE="JOURNAL_ARTICLE">
<AU>McGahan JP, Gu WZ, Brock JM, Tesluk H, Jones CD</AU>
<TI>Hepatic ablation using bipolar radiofrequency electrocautery</TI>
<SO>Academic Radiolology</SO>
<YR>1996</YR>
<VL>3</VL>
<PG>418-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2009" MODIFIED="2011-08-05 13:29:12 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group</AU>
<TI>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</TI>
<SO>PLoS Med</SO>
<YR>2009</YR>
<VL>6</VL>
<PG>e1000097</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulier-2005" MODIFIED="2012-04-27 21:23:58 +0200" MODIFIED_BY="[Empty name]" NAME="Mulier 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L</AU>
<TI>Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors</TI>
<SO>Annals of Surgery</SO>
<YR>2005</YR>
<VL>242</VL>
<PG>158-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulier-2008a" MODIFIED="2012-04-27 21:24:42 +0200" MODIFIED_BY="[Empty name]" NAME="Mulier 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T</AU>
<TI>Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>144-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulier-2008b" MODIFIED="2012-04-27 21:26:08 +0200" MODIFIED_BY="[Empty name]" NAME="Mulier 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Mulier S, Ruers T, Jamart J, Michel L, Marchal G, Ni Y</AU>
<TI>Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?</TI>
<SO>Digestive Surgery</SO>
<YR>2008</YR>
<VL>25</VL>
<PG>445-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schindl-2008" MODIFIED="2012-04-27 21:28:24 +0200" MODIFIED_BY="[Empty name]" NAME="Schindl 2008" TYPE="JOURNAL_ARTICLE">
<AU>Schindl M, Gruenberger Th, Längle F</AU>
<TI>Current strategies in the treatment of colorectal cancer liver metastases: aspects of surgical treatment</TI>
<SO>European Surgery</SO>
<YR>2008</YR>
<VL>16</VL>
<PG>332-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siperstein-2007" MODIFIED="2012-04-27 21:28:33 +0200" MODIFIED_BY="[Empty name]" NAME="Siperstein 2007" TYPE="JOURNAL_ARTICLE">
<AU>Siperstein AE, Berber E, Ballem N, Parikhn RT</AU>
<TI>Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience</TI>
<SO>Annals of Surgery</SO>
<YR>2007</YR>
<VL>246</VL>
<PG>559-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Solbiati-1997" MODIFIED="2012-04-27 21:27:24 +0200" MODIFIED_BY="[Empty name]" NAME="Solbiati 1997" TYPE="JOURNAL_ARTICLE">
<AU>Solbiati L, Ierace T, Goldberg SN, Sironi S, Livraghi T, Fiocca R, et al</AU>
<TI>Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients</TI>
<SO>Radiology</SO>
<YR>1997</YR>
<VL>202</VL>
<PG>195-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stroup-2000" MODIFIED="2012-04-27 21:32:34 +0200" MODIFIED_BY="[Empty name]" NAME="Stroup 2000" TYPE="JOURNAL_ARTICLE">
<AU>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al.</AU>
<TI>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group</TI>
<SO>Journal of American Medical Association</SO>
<YR>2000</YR>
<VL>283</VL>
<PG>2008-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tooth-2005" MODIFIED="2010-08-21 18:22:40 +0200" MODIFIED_BY="[Empty name]" NAME="Tooth 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tooth L, Ware R, Bain C, Purdie DM, Dobson A</AU>
<TI>Quality of reporting of observational longitudinal research</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2005</YR>
<VL>161</VL>
<PG>280-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsai-2009" MODIFIED="2012-04-27 21:31:19 +0200" MODIFIED_BY="[Empty name]" NAME="Tsai 2009" TYPE="JOURNAL_ARTICLE">
<AU>Tsai S, Pawlik TM</AU>
<TI>Outcomes of ablation versus resection for colorectal liver metastases: are we comparing apples with oranges?</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2009</YR>
<VL>16</VL>
<PG>2422-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vandenbroucke-2007" MODIFIED="2012-04-27 21:33:06 +0200" MODIFIED_BY="[Empty name]" NAME="Vandenbroucke 2007" TYPE="JOURNAL_ARTICLE">
<AU>Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al.</AU>
<TI>Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration</TI>
<SO>PLoS Med.</SO>
<YR>2007</YR>
<VL>16</VL>
<PG>e297</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Veltri-2008" MODIFIED="2012-04-27 21:33:37 +0200" MODIFIED_BY="[Empty name]" NAME="Veltri 2008" TYPE="JOURNAL_ARTICLE">
<AU>Veltri A, Sacchetto P, Tosetti I, Pagano E, Fava C, Gandini G</AU>
<TI>Radiofrequency ablation of colorectal liver metastases:small size favourably predicts technique effectiveness and survival</TI>
<SO>Cardiovascular Interventional Radiolology</SO>
<YR>2008</YR>
<VL>31</VL>
<PG>948&#8211;56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiss-1986" MODIFIED="2012-04-27 21:34:07 +0200" MODIFIED_BY="[Empty name]" NAME="Weiss 1986" TYPE="JOURNAL_ARTICLE">
<AU>Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al.</AU>
<TI>Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies</TI>
<SO>Journal of Pathology</SO>
<YR>1986</YR>
<VL>150</VL>
<PG>195-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitehead-1991" MODIFIED="2010-08-23 12:24:12 +0200" MODIFIED_BY="[Empty name]" NAME="Whitehead 1991" TYPE="JOURNAL_ARTICLE">
<AU>Whitehead A, Whitehead J.</AU>
<TI>A general parametric approach to the meta-analysis of randomized clinical trials.</TI>
<SO>Statistics in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>11</NO>
<PG>1665-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2011-07-14 11:22:19 +0200" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18316340"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Xu-2008" MODIFIED="2012-04-27 21:34:33 +0200" MODIFIED_BY="[Empty name]" NAME="Xu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Xu KC, Niu LZ, He WB, Hu YZ, Zuo JS</AU>
<TI>Percutaneous cryosurgery for the treatment of hepatic colorectal metastases</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>14</VL>
<PG>1430-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-08-13 17:17:50 +0200" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-03-21 13:29:59 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-03-21 13:29:59 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-09-16 22:47:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdalla-2004">
<CHAR_METHODS MODIFIED="2011-09-16 22:30:09 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on prospective database</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-16 22:47:48 +0200" MODIFIED_BY="[Empty name]">
<P>418 patients with CRLMs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-13 10:36:45 +0100" MODIFIED_BY="[Empty name]">
<P>190 HR vs 101 intraoperative RFA plus HR vs 57 intraoperative RFA only vs 70 systemic CT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-05 21:22:18 +0200" MODIFIED_BY="[Empty name]">
<P>OS - DFS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-13 10:36:09 +0100" MODIFIED_BY="[Empty name]">
<P>RFA alone or in association with HR was limited to cases in whom resection no permit complete resection leaving adequate liver parenchyma</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-30 14:45:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aloia-2006">
<CHAR_METHODS MODIFIED="2011-09-16 22:30:19 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on prospective database</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-30 14:45:32 +0200" MODIFIED_BY="[Empty name]">
<P>180 patients with solitary CR LM</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-05 11:01:34 +0200" MODIFIED_BY="[Empty name]">
<P>50 RFA vs 150 HR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-06 08:17:20 +0100" MODIFIED_BY="[Empty name]">
<P>Local and systemic recurrence. DFS. OS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-30 14:45:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berber-2008">
<CHAR_METHODS MODIFIED="2011-09-16 22:31:06 +0200" MODIFIED_BY="[Empty name]">
<P>A CCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-30 14:45:36 +0200" MODIFIED_BY="[Empty name]">
<P>158 patients with solitary CRLM</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-05 11:02:10 +0200" MODIFIED_BY="[Empty name]">
<P>68 RFA vs 90 HR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-05 11:07:12 +0200" MODIFIED_BY="[Empty name]">
<P>Peri-operative mortalities. Complication rate. OS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:32:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gleisner-2008">
<CHAR_METHODS MODIFIED="2011-09-16 22:32:21 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on prospective database</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-13 18:42:41 +0200" MODIFIED_BY="[Empty name]">
<P>258 patients with colorectal liver metastases who were operated on with curative intent were included in the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-13 18:41:13 +0200" MODIFIED_BY="[Empty name]">
<P>11 patients underwent RFA alone, 55 combined HR-RFA and 192 HR alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-25 22:06:41 +0200" MODIFIED_BY="[Empty name]">
<P>Recurrence, OS, DFS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-13 18:40:20 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:32:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hur-2009">
<CHAR_METHODS MODIFIED="2011-09-16 22:32:30 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on prospective database</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-22 18:25:27 +0100" MODIFIED_BY="[Empty name]">
<P>67 pts. with solitary CRLM</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-05 13:36:53 +0200" MODIFIED_BY="[Empty name]">
<P>RFA (25 pts.) v HR (42 pts.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-22 18:29:42 +0100" MODIFIED_BY="[Empty name]">
<P>Local and systemic recurrence. DFS. OS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:48:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2011">
<CHAR_METHODS MODIFIED="2011-09-16 22:34:28 +0200" MODIFIED_BY="[Empty name]">
<P>A CCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-16 22:48:11 +0200" MODIFIED_BY="[Empty name]">
<P>505 patients with CRLMs underwent RFA, hepatic resection or a combination<BR/>of RFA and resection at Asan Medical Center</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-25 22:03:03 +0200" MODIFIED_BY="[Empty name]">
<P>177 patients underwent RFA, 278 underwent hepatic resection and 27 underwent combination therapy for CRLM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-25 22:05:04 +0200" MODIFIED_BY="[Empty name]">
<P>OS, DFS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:48:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kornprat-2007">
<CHAR_METHODS MODIFIED="2011-09-16 22:34:35 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on prospective database</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-16 22:48:21 +0200" MODIFIED_BY="[Empty name]">
<P>Extensive CRLMs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-05 13:34:28 +0200" MODIFIED_BY="[Empty name]">
<P>HR with RFA (19 pts.) vs HR with CSA (20 pts.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-06 10:47:33 +0100" MODIFIED_BY="[Empty name]">
<P>Median intraoperative estimated blood loss, Median postoperative hospital stay, Morbidity, Mortality, Local recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 10:25:47 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:34:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2008">
<CHAR_METHODS MODIFIED="2011-09-16 22:34:56 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on prospective database</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-05 13:33:55 +0200" MODIFIED_BY="[Empty name]">
<P>153 pts. with solitary CRLM</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-05 13:37:26 +0200" MODIFIED_BY="[Empty name]">
<P>RFA (37 pts.) v HR (116 pts)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-05 13:37:56 +0200" MODIFIED_BY="[Empty name]">
<P>OS, DFS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:48:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McKay-2009">
<CHAR_METHODS MODIFIED="2011-09-16 22:35:05 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on prospective database</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-16 22:48:32 +0200" MODIFIED_BY="[Empty name]">
<P>50 pts. with CRCLMs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-13 17:46:41 +0100" MODIFIED_BY="[Empty name]">
<P>Intraoperative RFA (43 pts.) vs HR (58 pts.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-25 22:46:43 +0100" MODIFIED_BY="[Empty name]">
<P>Local recurrence rates, DFS and OS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:35:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oshowo-2003">
<CHAR_METHODS MODIFIED="2011-09-16 22:35:29 +0200" MODIFIED_BY="[Empty name]">
<P>CCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 05:41:56 +0100" MODIFIED_BY="[Empty name]">
<P>45 pts. with solitary CRLM</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-28 14:51:01 +0200" MODIFIED_BY="[Empty name]">
<P>RFA (25 pts.) vs HR (20 pts.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-17 09:50:27 +0200" MODIFIED_BY="[Empty name]">
<P>Post-operative mortality and morbility. Median survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:35:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Otto-2010">
<CHAR_METHODS MODIFIED="2011-09-16 22:35:40 +0200" MODIFIED_BY="[Empty name]">
<P>A CCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-05 14:39:36 +0200" MODIFIED_BY="[Empty name]">
<P>110 pts. with CRLMs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-05 14:50:05 +0200" MODIFIED_BY="[Empty name]">
<P>RFA (28 pts) vs HR (82 pts)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-13 17:27:08 +0200" MODIFIED_BY="[Empty name]">
<P>Recurrence at the site of ablation or resection, new metastases apart from the site of previous treatment, and systemic recurrence. Time to progression. OS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:48:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Park-2008">
<CHAR_METHODS MODIFIED="2011-09-16 22:36:09 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on prospective database</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-16 22:48:44 +0200" MODIFIED_BY="[Empty name]">
<P>89 patients with CRLMs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-28 14:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>RFA (30 pts.) vs RFA (59 pts.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-28 14:52:39 +0200" MODIFIED_BY="[Empty name]">
<P>Recurrence, OS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 13:22:47 +0100" MODIFIED_BY="[Empty name]">
<P>Presence of a subgroup with solitary CR LM</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-05 19:52:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reuter-2009">
<CHAR_METHODS MODIFIED="2011-09-16 22:36:18 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on prospective database</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-28 14:44:57 +0200" MODIFIED_BY="[Empty name]">
<P>186 patients with CRC LMs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-28 14:46:00 +0200" MODIFIED_BY="[Empty name]">
<P>RFA (66 pts.) vs 126 (pts.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-28 14:47:10 +0200" MODIFIED_BY="[Empty name]">
<P>Complications, Recurrence, and Overall Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-05 19:52:37 +0100" MODIFIED_BY="[Empty name]">
<P>There is a partial overlapping data with patients in <LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK> study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:48:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruers-2010">
<CHAR_METHODS MODIFIED="2011-08-05 11:00:06 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-16 22:48:57 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with &#8804; 9 unresectable CRLMs and no extrahepatic disease 119 pts</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-13 10:38:26 +0100" MODIFIED_BY="[Empty name]">
<P>Systemic CT alone (FOLFOX, oxaliplatin 85 mg/m<SUP>2</SUP> and LV5FU2, and since October 2005 plus bevacizumab) vs RFA plus systemic CT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-16 18:11:19 +0200" MODIFIED_BY="[Empty name]">
<P>30-months OS rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-16 18:27:56 +0200" MODIFIED_BY="[Empty name]">
<P>A abstract at the 2010 ASCO Annual Meeting</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 13:29:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scaife-2003">
<CHAR_METHODS MODIFIED="2011-09-16 22:36:38 +0200" MODIFIED_BY="[Empty name]">
<P>A CCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-28 14:52:56 +0200" MODIFIED_BY="[Empty name]">
<P>50 pts. CRLMs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-28 15:01:00 +0200" MODIFIED_BY="[Empty name]">
<P>Intraoperative RFA with adjuvant HAI ( 19 pts.) versus intraoperative RFA, adjuvant HAI, and HR (31 pts.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-21 13:29:59 +0100" MODIFIED_BY="[Empty name]">
<P>OS - Postoperative complications -Chemotherapy-related toxicity - Pump/catheter complications - Local tumour recurrence -<BR/>New intrahepatic metastases</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:36:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schiffman-2010">
<CHAR_METHODS MODIFIED="2011-09-16 22:36:54 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on prospective database</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-22 21:52:09 +0100" MODIFIED_BY="[Empty name]">
<P>140 pts. with solitary CRLM</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-28 14:55:25 +0200" MODIFIED_BY="[Empty name]">
<P>HR (45 pts.) vs RFA (95 pts.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-22 21:53:26 +0100" MODIFIED_BY="[Empty name]">
<P>DFS - OS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:49:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vyslouzil-2009">
<CHAR_METHODS MODIFIED="2011-09-16 22:37:05 +0200" MODIFIED_BY="[Empty name]">
<P>A CCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-16 22:49:04 +0200" MODIFIED_BY="[Empty name]">
<P>190 pts. with CRLMs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-13 22:15:13 +0200" MODIFIED_BY="[Empty name]">
<P>HR in 136 patients, RFA combined with HR in 23 patients and RFA 31 patients (16 %).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-13 22:15:27 +0200" MODIFIED_BY="[Empty name]">
<P>OS - DFS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-13 22:16:03 +0200" MODIFIED_BY="[Empty name]">
<P>Article in German</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-16 22:49:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-2007">
<CHAR_METHODS MODIFIED="2011-09-16 22:37:56 +0200" MODIFIED_BY="[Empty name]">
<P>A CCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-16 22:49:12 +0200" MODIFIED_BY="[Empty name]">
<P>52 patients with solitary CRLMs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-28 14:57:44 +0200" MODIFIED_BY="[Empty name]">
<P>RFA (22 pts.) vs HR (30 pts.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-06 15:25:28 +0100" MODIFIED_BY="[Empty name]">
<P>PFS, OS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 15:24:40 +0100" MODIFIED_BY="[Empty name]">
<P>The HR was only nonanatomic wedge resection</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-09-16 22:51:41 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:49:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x002d_Asfoor-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:49:22 +0200" MODIFIED_BY="[Empty name]">
<P>A systematic review on resection versus no intervention or other surgical interventions for CRLMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:49:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Curley-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:49:26 +0200" MODIFIED_BY="[Empty name]">
<P>A editorial on RFA in CRLMs. The editorial do not contain original research</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:49:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Jong-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:49:36 +0200" MODIFIED_BY="[Empty name]">
<P>A multi-institutional retrospective analysis on recurrence in patients following curative intent surgery for CRLMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:49:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Doyle-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:49:40 +0200" MODIFIED_BY="[Empty name]">
<P>A editorial on RFA for resectable CRLMs<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:49:51 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elias-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:49:51 +0200" MODIFIED_BY="[Empty name]">
<P>A CCT: RFA vs HR in treatment of LMs (CR, endocrine tumours, breast, sarcoma melanoma, etc.). It is not possible extract the data of only CRLMs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:49:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frich-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:49:54 +0200" MODIFIED_BY="[Empty name]">
<P>A systematic review on local ablation of non-resectable CRLMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-16 16:08:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frich-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-16 16:08:04 +0200" MODIFIED_BY="[Empty name]">
<P>A prospective non-randomized study on colorectal non-resectable LMs: 10 patients treated only with RFA vs 7 patients treated with RFA combined with liver resection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:50:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grundmann-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:50:21 +0200" MODIFIED_BY="[Empty name]">
<P>A economic analysis of treatment for CRLMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-16 17:49:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jansen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-16 17:49:55 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis of the SIR's degree after RFA vs major or minor liver resection for liver tumours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:50:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Joosten-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:50:32 +0200" MODIFIED_BY="[Empty name]">
<P>A retrospective analysis on immediate local treatment of cryosurgical ablation vs RFA in patients with non-resectable CRLMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:50:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leblanc-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:50:40 +0200" MODIFIED_BY="[Empty name]">
<P>A CCT: RFA vs HR in treatment of LMs (CR, endocrine tumours, breast, sarcoma testicle, etc.). It is not possible extract the data of only CRLMs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:50:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:50:49 +0200" MODIFIED_BY="[Empty name]">
<P>A review on RFA for CRLMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-16 16:35:17 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lupo-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-16 16:35:17 +0200" MODIFIED_BY="[Empty name]">
<P>A RCT on radiofrequency-assisted liver resection vs RFA in HCCs and LMs </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:51:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:51:03 +0200" MODIFIED_BY="[Empty name]">
<P>A phase II study on RFA or resection/ablation with adjuvant hepatic arterial infusion in CRLMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:51:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mulier-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:51:08 +0200" MODIFIED_BY="[Empty name]">
<P>A review on RFA for CRLMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:51:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pawlik-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:51:22 +0200" MODIFIED_BY="[Empty name]">
<P>A analysis on combined hepatic resection and RFA for 172 patients with multifocal hepatic malignancies (124 with colorectal metastases; 48 with non colorectal metastases)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-16 22:51:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reurs-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-16 22:51:41 +0200" MODIFIED_BY="[Empty name]">
<P>A CCT on 201 pts., without extrahepatic disease, underwent laparotomy for surgical treatment of liver metastases: HR (117 pts.) vs local tumour ablation (cryoablation or radiofrequency) ± HR (45 pts.) vs systemic chemotherapy (39 pts.). It is not possible distinguished the different results between cryoablation (18 pts.) or radiofrequency (27 pts.).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-16 17:31:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scott-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-16 17:31:23 +0200" MODIFIED_BY="[Empty name]">
<P>A RCT on laparoscopic vs open hepatic RFA for hepatic tumours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-16 17:36:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stang-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-16 17:36:06 +0200" MODIFIED_BY="[Empty name]">
<P>A systematic review on RFA in LMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-16 17:36:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sutherland-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-16 17:36:12 +0200" MODIFIED_BY="[Empty name]">
<P>A systematic review on RFA in HCCs and LMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-16 17:46:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tez-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-16 17:46:09 +0200" MODIFIED_BY="[Empty name]">
<P>A letter to the Editor. The letter do not contain original research</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-16 17:35:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wong-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-16 17:35:50 +0200" MODIFIED_BY="[Empty name]">
<P>A systematic review on hepatic resection vs RFA in HCCs and LMs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-08-20 07:45:10 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-09-11 07:05:53 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-09-11 07:04:05 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-09-11 07:04:05 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-09-11 07:04:05 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-09-11 07:04:05 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-11-13 07:54:23 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2012-05-09 11:03:51 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-05-09 11:02:50 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-09-02 18:41:57 +0200" MODIFIED_BY="[Empty name]">Overview of trials included in the meta-analysis: RFA vs HR</TITLE>
<TABLE COLS="10" ROWS="14">
<TR>
<TD ALIGN="CENTER">
<P>Author<BR/>(year)</P>
</TD>
<TD ALIGN="CENTER">
<P>Treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Patients</P>
<P>(n)</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean tumour<BR/>size [range]<BR/>(cm)</P>
</TD>
<TD ALIGN="CENTER">
<P>Utilization of RFA</P>
</TD>
<TD ALIGN="CENTER">
<P>Median<BR/>follow-up [range] (months)</P>
</TD>
<TD ALIGN="CENTER">
<P>OS</P>
<P>(3 years)</P>
</TD>
<TD ALIGN="CENTER">
<P>OS</P>
<P>(5 years)</P>
</TD>
<TD ALIGN="CENTER">
<P>OS</P>
<P>median</P>
<P>(months)</P>
</TD>
<TD ALIGN="CENTER">
<P>DFS</P>
<P>(5 years)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Oshowo-2003" TYPE="STUDY">Oshowo 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>percutaneous RFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P>25</P>
<P>20</P>
</TD>
<TD ALIGN="CENTER">
<P>3 [1&#8211;10]</P>
<P>4 [2&#8211;7]</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable solitary CRLM (extrahepatic disease, vessel contiguity, co-morbidity)</P>
</TD>
<TD ALIGN="CENTER">
<P>18</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>53%</P>
<P>55%</P>
</TD>
<TD ALIGN="CENTER">
<P>-----</P>
</TD>
<TD ALIGN="CENTER">
<P>37</P>
<P>41</P>
</TD>
<TD ALIGN="CENTER">
<P>-----</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Aloia-2006" TYPE="STUDY">Aloia 2006</LINK> </P>
</TD>
<TD ALIGN="CENTER">
<P>open RFA</P>
<P>percutaneous RFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
<P>3</P>
<P/>
<P>160</P>
</TD>
<TD ALIGN="CENTER">
<P>3 [1&#8211;7]</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable solitary CRLM (when HR not have left an adequate hepatic residual parenchyma or the comorbidity precluded adequate HR)</P>
</TD>
<TD ALIGN="CENTER">
<P>31.3</P>
<P>(4-138)</P>
</TD>
<TD ALIGN="CENTER">
<P>57%</P>
<P/>
<P>79%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>27%</P>
<P/>
<P>71%</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>-----</P>
<P/>
<P>-----</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
<P/>
<P>50%</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-White-2007" TYPE="STUDY">White 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>percutaneous RFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P>22</P>
<P>30</P>
</TD>
<TD ALIGN="CENTER">
<P>2.4 [1&#8211;5]</P>
<P>2.7 [1&#8211;5]</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable solitary CRLM (RFA was used in prior major hepatectomy, major medical co-morbidities, or relative un resectability</P>
</TD>
<TD ALIGN="CENTER">
<P>17</P>
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>26%</P>
<P>82%</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
<P>57%</P>
</TD>
<TD ALIGN="CENTER">
<P>31</P>
<P>80</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
<P>32%</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Park-2008" TYPE="STUDY">Park 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>percutaneous RFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P>30</P>
<P>59</P>
</TD>
<TD ALIGN="CENTER">
<P>2.0 [0.6&#8211;4]</P>
<P>3.1 [0.5&#8211;8]</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable CRLMs (co-morbidity, patients avoided HR or when hepatic residual parenchyma after HR was not adequate)</P>
</TD>
<TD ALIGN="CENTER">
<P>49</P>
<P>(10&#8211;149)</P>
</TD>
<TD ALIGN="CENTER">
<P>-----</P>
<P>-----</P>
</TD>
<TD ALIGN="CENTER">
<P>19%</P>
<P>48%</P>
</TD>
<TD ALIGN="CENTER">
<P>36</P>
<P>56</P>
</TD>
<TD ALIGN="CENTER">
<P>-------</P>
<P>-------</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>openRFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
<P>192</P>
</TD>
<TD ALIGN="CENTER">
<P>2.5</P>
<P>3.5</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable CRLMs (location of the disease, inadequate liver remnant,<BR/>proximity of tumour to major vascular structures, major medical co-morbidities)</P>
</TD>
<TD ALIGN="CENTER">
<P>-------</P>
</TD>
<TD ALIGN="CENTER">
<P>72.7%</P>
<P>74.1%</P>
</TD>
<TD ALIGN="CENTER">
<P>------</P>
</TD>
<TD ALIGN="CENTER">
<P>-------------</P>
</TD>
<TD ALIGN="CENTER">
<P>--------</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>open or</P>
<P>percutaneous</P>
<P>RFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>37</P>
<P>116</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>2.25 (0.8-5.0)</P>
<P>3.29 (0.5-18.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>refusal of surgery, an insufficient hepatic reserve for surgery on Indocyanine Green test, and<BR/>co-morbidities (15 patients) such as severe chronic<BR/>obstructive pulmonary disorder, congestive heart failure that precluded from safe HR</P>
</TD>
<TD ALIGN="CENTER">
<P>53%</P>
<P/>
<P>88%</P>
</TD>
<TD ALIGN="CENTER">
<P>43%</P>
<P/>
<P>83%</P>
</TD>
<TD>
<P>48.5%</P>
<P/>
<P>65.7%</P>
</TD>
<TD ALIGN="CENTER">
<P>38.2 months (0.1-132.8)</P>
<P/>
<P>48.2 (0.9<BR/>- 133.9)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>25.7%</P>
<P/>
<P>30.1%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Berber-2008" TYPE="STUDY">Berber 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Laparoscopic</P>
<P>RFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
<P>90</P>
</TD>
<TD ALIGN="CENTER">
<P>3.7±0.2</P>
<P>3.8±0.2</P>
</TD>
<TD ALIGN="CENTER">
<P>technical reasons, patient co-morbidities, extra-hepatic disease, patient decision</P>
</TD>
<TD ALIGN="CENTER">
<P>27 (2&#8211;86)</P>
<P>41(2&#8211;132)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>35%</P>
<P>70%</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>30%</P>
<P>40%</P>
</TD>
<TD ALIGN="CENTER">
<P>--------</P>
</TD>
<TD ALIGN="CENTER">
<P>------</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hur-2009" TYPE="STUDY">Hur 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>open RFA</P>
<P>percutaneous RFA</P>
<P/>
<P>HR</P>
<P/>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>13</P>
<P/>
<P>12</P>
<P/>
<P>42</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>2.5 (0.8&#8211;3.6)</P>
<P/>
<P>2.8</P>
<P>(0.6&#8211;8)</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>unresectable solitary CRLM (located<BR/>close to or involving a major vessel, insufficient functional hepatic reserve after HR, the patient&#8217;s co-morbidities inhibited a major surgery or the patients preferred to be treated by RFA</P>
</TD>
<TD ALIGN="CENTER">
<P>42</P>
<P>(13&#8211;120)</P>
</TD>
<TD ALIGN="CENTER">
<P>60%</P>
<P/>
<P>70%</P>
</TD>
<TD ALIGN="CENTER">
<P>26%</P>
<P/>
<P/>
<P>50%</P>
</TD>
<TD ALIGN="CENTER">
<P>41</P>
<P/>
<P>60</P>
</TD>
<TD ALIGN="CENTER">
<P>-------</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>open or percutaneous RFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>31</P>
<P>136</P>
</TD>
<TD ALIGN="CENTER">
<P>-----</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable CRLMs (In this trial is not show the exact reason why patients have a unresectable disease)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>26%</P>
<P>58%</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>open RFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P>43</P>
<P>58</P>
</TD>
<TD ALIGN="CENTER">
<P>4.1 [1&#8211;7.5]</P>
<P>3 [1.2-7]</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable CRLMs (In this trial is not show the exact reason why patients have a unresectable disease)</P>
</TD>
<TD ALIGN="CENTER">
<P>42 (15-85)</P>
<P>25 (4-106)</P>
</TD>
<TD ALIGN="CENTER">
<P>-----</P>
</TD>
<TD ALIGN="CENTER">
<P>23%</P>
<P>43%</P>
</TD>
<TD ALIGN="CENTER">
<P>---------</P>
</TD>
<TD ALIGN="CENTER">
<P>15%</P>
<P>17%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Otto-2010" TYPE="STUDY">Otto 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>open RFA</P>
<P>percutaneous</P>
<P>RFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P>28</P>
<P>82</P>
</TD>
<TD ALIGN="CENTER">
<P>3 (1&#8211;5)</P>
<P>5 (1&#8211;14)</P>
</TD>
<TD ALIGN="CENTER">
<P>CRLMs detected within the first year after colorectal surgery preferentially by RFA</P>
</TD>
<TD ALIGN="CENTER">
<P>814 (49&#8211;1642)</P>
<P>644 (7&#8211;2452)</P>
</TD>
<TD ALIGN="CENTER">
<P>67%</P>
<P/>
<P>60%</P>
</TD>
<TD ALIGN="CENTER">
<P>48%</P>
<P/>
<P>51%</P>
</TD>
<TD ALIGN="CENTER">
<P>---------</P>
</TD>
<TD ALIGN="CENTER">
<P>------</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Schiffman-2010" TYPE="STUDY">Schiffman 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>RFA</P>
<P>HR</P>
</TD>
<TD ALIGN="CENTER">
<P>46</P>
<P>94</P>
</TD>
<TD ALIGN="CENTER">
<P>3.9</P>
<P>5.6</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable solitary CRLM (HR were not feasible for co-morbidity, when patients avoided HR or when hepatic residual parenchyma after HR was not adequate)</P>
</TD>
<TD ALIGN="CENTER">
<P>25.9</P>
</TD>
<TD ALIGN="CENTER">
<P>-----</P>
</TD>
<TD ALIGN="CENTER">
<P>-------</P>
</TD>
<TD ALIGN="CENTER">
<P>112.7</P>
<P>50.2</P>
</TD>
<TD ALIGN="CENTER">
<P>42.6 months</P>
<P/>
<P>55.2 months</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>open or</P>
<P>percutaneous</P>
<P>RFA</P>
<P>HR</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>99</P>
<P>127</P>
</TD>
<TD>
<P>2.1 ± 1.0</P>
<P>2.6 ± 2.0</P>
</TD>
<TD ALIGN="CENTER">
<P>surgery-prohibitive comorbidities, difficult anatomical site for surgical resection, and more than four LMs over the entire liver</P>
</TD>
<TD ALIGN="CENTER">
<P>----</P>
</TD>
<TD ALIGN="CENTER">
<P>50.3%<BR/>62%</P>
</TD>
<TD>
<P>31.2%<BR/>45.3%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>23.1%</P>
<P>36.6%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-05-09 11:03:51 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-09-02 19:14:18 +0200" MODIFIED_BY="[Empty name]">Overview of trials included in the meta-analysis: RFA plus systemic CT versus systemic CT alone</TITLE>
<TABLE COLS="7" ROWS="2">
<TR>
<TD ALIGN="CENTER">
<P>Author<BR/>(year)</P>
</TD>
<TD ALIGN="CENTER">
<P>Treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Patients</P>
<P>(n)</P>
</TD>
<TD ALIGN="CENTER">
<P>Utilization of RFA</P>
</TD>
<TD ALIGN="CENTER">
<P>Median<BR/>follow-up</P>
</TD>
<TD ALIGN="CENTER">
<P>OS</P>
<P>(30-months )</P>
</TD>
<TD ALIGN="CENTER">
<P>PFS</P>
<P>(median)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ruers-2010" TYPE="STUDY">Ruers 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>RFA plus CT</P>
<P>CT</P>
</TD>
<TD ALIGN="CENTER">
<P>60</P>
<P>59</P>
</TD>
<TD>
<P>patients with &#8804;9 unresectable CRLMs and no extrahepatic<SUP> </SUP>disease</P>
</TD>
<TD ALIGN="CENTER">
<P>4.4 years</P>
</TD>
<TD ALIGN="CENTER">
<P>61.7%</P>
<P>57.6%</P>
</TD>
<TD ALIGN="CENTER">
<P>16.8 months</P>
<P>9.9 months</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2011-09-30 14:46:34 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-09-02 19:15:44 +0200" MODIFIED_BY="[Empty name]">Overview of trials included in the meta-analysis: RFA plus HAI vs RFA plus HAI and HR</TITLE>
<TABLE COLS="9" ROWS="2">
<TR>
<TD ALIGN="CENTER">
<P>Author<BR/>(year)</P>
</TD>
<TD ALIGN="CENTER">
<P>Treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Patients</P>
<P>(n)</P>
</TD>
<TD ALIGN="CENTER">
<P>Utilization of RFA</P>
</TD>
<TD ALIGN="CENTER">
<P>Local tumour recurrence</P>
<P>(Median follow-up, 20 months)</P>
</TD>
<TD ALIGN="CENTER">
<P>New intrahepatic metastases</P>
<P>(Median follow-up, 20 months)</P>
</TD>
<TD ALIGN="CENTER">
<P>No evidence of disease</P>
<P>(Median follow-up, 20 months)</P>
</TD>
<TD ALIGN="CENTER">
<P>Alive with disease</P>
<P>(Median follow-up, 20 months)</P>
</TD>
<TD ALIGN="CENTER">
<P>Dead<BR/>of disease</P>
<P>(Median follow-up, 20 months)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Scaife-2003" TYPE="STUDY">Scaife 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>RFA combined with HAI</P>
<P>RFA combined with HAI and HR</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
<P/>
<P>31</P>
</TD>
<TD ALIGN="CENTER">
<P>Patients with seven or fewer metastatic lesions, that could<BR/>not be resected but that were amenable to RFA alone or<BR/>RFA of smaller tumours combined with resection of large<BR/>lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>16%</P>
<P/>
<P>6%</P>
</TD>
<TD ALIGN="CENTER">
<P>37%</P>
<P/>
<P>26%</P>
</TD>
<TD ALIGN="CENTER">
<P>26%</P>
<P/>
<P>36%</P>
</TD>
<TD ALIGN="CENTER">
<P>47%</P>
<P/>
<P>26%</P>
</TD>
<TD ALIGN="CENTER">
<P>26%</P>
<P/>
<P>39%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2011-09-30 14:46:43 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-09-02 19:17:36 +0200" MODIFIED_BY="[Empty name]">Overview of trials included in the meta-analysis: RFA plus HR vs HR vs RFA vs systemic CT</TITLE>
<TABLE COLS="10" ROWS="2">
<TR>
<TD ALIGN="CENTER">
<P>Author<BR/>(year)</P>
</TD>
<TD ALIGN="CENTER">
<P>Treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Patients</P>
<P>(n)</P>
</TD>
<TD ALIGN="CENTER">
<P>Utilization of RFA</P>
</TD>
<TD ALIGN="CENTER">
<P>Recurrence of any site</P>
</TD>
<TD ALIGN="CENTER">
<P>Intrahepatic recurrence only</P>
</TD>
<TD ALIGN="CENTER">
<P>True local<BR/>recurrence</P>
</TD>
<TD ALIGN="CENTER">
<P>OS</P>
<P>(3-year<BR/>survival)</P>
</TD>
<TD ALIGN="CENTER">
<P>OS</P>
<P>(4-year<BR/>survival)</P>
</TD>
<TD ALIGN="CENTER">
<P>OS</P>
<P>(5-year<BR/>survival)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Abdalla-2004" TYPE="STUDY">Abdalla 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>HR</P>
<P>RFA plus HR</P>
<P>RFA</P>
<P>CT</P>
</TD>
<TD ALIGN="CENTER">
<P>190</P>
<P>101</P>
<P>57</P>
<P>70</P>
</TD>
<TD ALIGN="CENTER">
<P>tumour near a major hepatic vein branch or the inferior<BR/>vena cava</P>
</TD>
<TD ALIGN="CENTER">
<P>52%</P>
<P>63%</P>
<P>84%</P>
<P>-----</P>
</TD>
<TD ALIGN="CENTER">
<P>11%</P>
<P>28%</P>
<P>44%</P>
<P>-----</P>
</TD>
<TD ALIGN="CENTER">
<P>2%</P>
<P>5%</P>
<P>9%</P>
<P>----</P>
</TD>
<TD ALIGN="CENTER">
<P>73%</P>
<P>43%</P>
<P>37%</P>
<P>----</P>
</TD>
<TD ALIGN="CENTER">
<P>65%</P>
<P>36%</P>
<P>22%</P>
<P>----</P>
</TD>
<TD ALIGN="CENTER">
<P>58%</P>
<P/>
<P/>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2011-09-30 14:46:51 +0200" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-09-02 19:19:33 +0200" MODIFIED_BY="[Empty name]">Overview of trials included in the meta-analysis: RFA plus HR vs CSA plus HR</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TD ALIGN="CENTER">
<P>Author<BR/>(year)</P>
</TD>
<TD ALIGN="CENTER">
<P>Treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Patients</P>
<P>(n)</P>
</TD>
<TD ALIGN="CENTER">
<P>Utilization of RFA</P>
</TD>
<TD ALIGN="CENTER">
<P>Local in situ recurrence</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Kornprat-2007" TYPE="STUDY">Kornprat 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>HR plus intraoperative RFA</P>
<P>HR plus intraoperative CSA</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
<P/>
<P>20</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable CRLMs (in this trial is not show the exact reason why patients have a unresectable disease)</P>
</TD>
<TD ALIGN="CENTER">
<P>14%</P>
<P/>
<P>12%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2012-03-21 13:31:15 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2011-09-13 07:00:06 +0200" MODIFIED_BY="[Empty name]">Overview of trials included in the meta-analysis: HR vs HR plus RFA</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Patients</P>
<P>(n)</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean tumour<BR/>size [range]<BR/>(cm)</P>
</TD>
<TD ALIGN="CENTER">
<P>Utilization of RFA</P>
</TD>
<TD>
<P>Median<BR/>follow-up [range] (months)</P>
</TD>
<TD ALIGN="CENTER">
<P>OS</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gleisner-2008" TYPE="STUDY">Gleisner 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>HR plus RFA</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>55</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>2.5</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable CRLMs (location of the disease, inadequate liver remnant, proximity of tumour to major vascular structures, major medical co-morbidities)</P>
</TD>
<TD ALIGN="CENTER">
<P>-------</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>44.9%</P>
<P>(3-years)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vyslouzil-2009" TYPE="STUDY">Vyslouzil 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>HR plus RFA</P>
</TD>
<TD ALIGN="CENTER">
<P>23</P>
</TD>
<TD ALIGN="CENTER">
<P>---</P>
</TD>
<TD ALIGN="CENTER">
<P>------------------------</P>
</TD>
<TD ALIGN="CENTER">
<P>------</P>
</TD>
<TD ALIGN="CENTER">
<P>30%</P>
<P>(3-years)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-McKay-2009" TYPE="STUDY">McKay 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>HR plus RFA</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>4.8 [1.2-7]</P>
</TD>
<TD ALIGN="CENTER">
<P>unresectable CRLMs (In this trial is not show the exact reason why patients have a unresectable disease)</P>
</TD>
<TD ALIGN="CENTER">
<P>20 (15-45)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.3</P>
<P>(median)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>HR plus RFA</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="CENTER">
<P>2.1</P>
</TD>
<TD ALIGN="CENTER">
<P>surgery-prohibitive co-morbidities, difficult anatomical site for surgical resection, and more than four LMs over the entire liver</P>
</TD>
<TD ALIGN="CENTER">
<P>------------</P>
</TD>
<TD ALIGN="CENTER">
<P>22.9%</P>
<P>(5 years)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2012-03-21 13:33:01 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2011-09-13 00:18:27 +0200" MODIFIED_BY="[Empty name]">Methodological quality of non-randomized trial</TITLE>
<TABLE COLS="20" ROWS="47">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Item No</P>
</TD>
<TD VALIGN="BOTTOM">
<P>Recommendation</P>
</TD>
<TD VALIGN="TOP">
<P>Oshowo</P>
</TD>
<TD VALIGN="TOP">
<P>Abdalla</P>
</TD>
<TD VALIGN="TOP">
<P>White</P>
</TD>
<TD VALIGN="TOP">
<P>Lee</P>
</TD>
<TD VALIGN="TOP">
<P>Kornprat</P>
</TD>
<TD VALIGN="TOP">
<P>Hur</P>
</TD>
<TD VALIGN="TOP">
<P>Gleisner</P>
</TD>
<TD VALIGN="TOP">
<P>Berber</P>
</TD>
<TD VALIGN="TOP">
<P>Schiffman</P>
</TD>
<TD VALIGN="TOP">
<P>Park</P>
</TD>
<TD VALIGN="TOP">
<P>Aloia</P>
</TD>
<TD VALIGN="TOP">
<P>Otto</P>
</TD>
<TD VALIGN="TOP">
<P>Vyslouz&#711;il</P>
</TD>
<TD VALIGN="TOP">
<P>Kim</P>
</TD>
<TD VALIGN="TOP">
<P>Reuter</P>
</TD>
<TD VALIGN="TOP">
<P>Scaife</P>
</TD>
<TD VALIGN="TOP">
<P>McKay</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Title and abstract</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>(<I>a</I>) Indicate the study&#8217;s design with a commonly used term in the title or the abstract</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(<I>b</I>) Provide in the abstract an informative and balanced summary of what was done and what was found</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>Introduction</P>
</TD>
<TD COLSPAN="15" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Background/rationale</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>Explain the scientific background and rationale for the investigation being reported</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Objectives</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>State specific objectives, including any prespecified hypotheses</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>Methods</P>
</TD>
<TD COLSPAN="8" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Study design</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>Present key elements of study design early in the paper</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Setting</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</P>
</TD>
<TD VALIGN="TOP">
<P>Yes, No, No, No, No,  No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes, Yes, Yes, Yes,</P>
<P>Yes, Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes,</P>
<P>No,</P>
<P>No, No, Yes, No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes, Yes, Yes, Yes,</P>
<P>Yes, Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes, Yes, Yes, Yes,</P>
<P>Yes, Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes, Yes, Yes, Yes,</P>
<P>Yes, Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes,</P>
<P>Yes,</P>
<P>Yes,</P>
<P> Yes,</P>
<P>Yes,</P>
<P> Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No</P>
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes, Yes, Yes, Yes,</P>
<P>Yes, Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes Yes Yes Yes</P>
<P>YesYes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes, Yes, No, No,</P>
<P>No, Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes, Yes, Yes, Yes,</P>
<P>Yes, Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes,</P>
<P>Yes,</P>
<P>Yes,</P>
<P>Yes,</P>
<P>Yes,</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes,</P>
<P>Yes,</P>
<P>Yes,</P>
<P>Yes,</P>
<P>Yes,</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes,</P>
<P>Yes,</P>
<P>Yes,</P>
<P>Yes,</P>
<P>Yes,</P>
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="5" VALIGN="TOP">
<P>Participants</P>
<P> </P>
</TD>
<TD ROWSPAN="5" VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>(<I>a</I>) <I>Cohort study</I>&#8212;Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Case-control study</I>&#8212;Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Cross-sectional study</I>&#8212;Give the eligibility criteria, and the sources and methods of selection of participants</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(<I>b</I>)<B> </B>
<I>Cohort study</I>&#8212;For matched studies, give matching criteria and number of exposed and unexposed</P>
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Case-control study</I>&#8212;For matched studies, give matching criteria and the number of controls per case</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Variables</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</P>
</TD>
<TD VALIGN="TOP">
<P>No,</P>
<P>Yes,</P>
<P>No,</P>
<P>No</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No,</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes Yes</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes, Yes, Yes, Yes,</P>
<P>Yes, Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>No</P>
<P>No</P>
<P>No</P>
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Data sources/ measurement</P>
</TD>
<TD VALIGN="TOP">
<P>8*</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>No</I>
</P>
<P>
<I>No</I>
</P>
<P>
<I>No</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>No</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P>
<I>No</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Bias</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>Describe any efforts to address potential sources of bias</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Study size</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>Explain how the study size was arrived at</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Quantitative variables</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="7" VALIGN="TOP">
<P>Statistical methods</P>
</TD>
<TD ROWSPAN="7" VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>(<I>a</I>) Describe all statistical methods, including those used to control for confounding</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes </P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P>
<I>Yes</I>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No per confounders</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(<I>b</I>) Describe any methods used to examine subgroups and interactions</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(<I>c</I>) Explain how missing data were addressed</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(<I>d</I>) <I>Cohort study</I>&#8212;If applicable, explain how loss to follow-up was addressed</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Case-control study</I>&#8212;If applicable, explain how matching of cases and controls was addressed</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Cross-sectional study</I>&#8212;If applicable, describe analytical methods taking account of sampling strategy</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(<U>
<I>e</I>
</U>) Describe any sensitivity analyses</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Results</B>
</P>
</TD>
<TD COLSPAN="8" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Participants</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>(a) Report numbers of individuals at each stage of study&#8212;e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(b) Give reasons for non-participation at each stage</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(c) Consider use of a flow diagram</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Descriptive data</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>14*</P>
</TD>
<TD VALIGN="TOP">
<P>(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
<TD VALIGN="TOP">
<P>Yes characteristic</P>
<P>No confounders</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(b) Indicate number of participants with missing data for each variable of interest</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(c) <I>Cohort study</I>&#8212;Summarise follow-up time (e.g., average and total amount)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Outcome data</P>
</TD>
<TD VALIGN="TOP">
<P>15*</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Cohort study</I>&#8212;Report numbers of outcome events or summary measures over time</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Case-control study&#8212;</I>Report numbers in each exposure category, or summary measures of exposure</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Yes</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Cross-sectional study&#8212;</I>Report numbers of outcome events or summary measures</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Main results</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>(<I>a</I>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P>Yes</P>
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(<I>b</I>) Report category boundaries when continuous variables were categorized</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(<I>c</I>) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other analyses</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>Report other analyses done&#8212;e.g. analyses of subgroups and interactions, and sensitivity analyses</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Discussion</B>
</P>
</TD>
<TD COLSPAN="8" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Key results</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>Summarise key results with reference to study objectives</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Limitations</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Interpretation</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Generalisability</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>Discuss the generalisability (external validity) of the study results</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Other information</B>
</P>
</TD>
<TD COLSPAN="8" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Funding</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>Give the source of funding and the role of the founders for the present study and, if applicable, for the original study on which the present article is based</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-03-15 18:57:52 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-03-15 18:57:06 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>30 day post-operative mortality</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-03-15 18:57:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="464" TOTAL_2="845" WEIGHT="0.0" Z="0.0">
<NAME>Postoperative mortality</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>HR</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RFA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HR</GRAPH_LABEL_2>
<DICH_DATA CI_END="41.06549298371077" CI_START="0.06500745385412732" EFFECT_SIZE="1.633879781420765" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.6134770408202215" LOG_CI_START="-1.1870368436322212" LOG_EFFECT_SIZE="0.21322009859400018" MODIFIED="2012-03-15 18:56:57 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="1.6450357184946687" STUDY_ID="STD-Aloia-2006" TOTAL_1="30" TOTAL_2="150" VAR="2.7061425151232705" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-15 18:56:57 +0100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.0" STUDY_ID="STD-Berber-2008" TOTAL_1="68" TOTAL_2="90" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-15 18:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.0" STUDY_ID="STD-Hur-2009" TOTAL_1="25" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-15 18:56:59 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.0" STUDY_ID="STD-Kim-2011" TOTAL_1="177" TOTAL_2="278" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="103.85848938217993" CI_START="0.16418534126510365" EFFECT_SIZE="4.129411764705883" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.016442001508078" LOG_CI_START="-0.7846656200050154" LOG_EFFECT_SIZE="0.6158881907515313" MODIFIED="2012-03-15 18:56:59 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="1.6453844825831407" STUDY_ID="STD-McKay-2009" TOTAL_1="43" TOTAL_2="58" VAR="2.70729009552539" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.603417744007174" CI_START="0.00983960308594058" EFFECT_SIZE="0.2549019607843137" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8197687723871164" LOG_CI_START="-2.007022419969316" LOG_EFFECT_SIZE="-0.5936268237910997" MODIFIED="2012-03-15 18:57:00 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="1.6604711392322442" STUDY_ID="STD-Oshowo-2003" TOTAL_1="25" TOTAL_2="20" VAR="2.7571644042232273" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-15 18:57:00 +0100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.0" STUDY_ID="STD-Otto-2010" TOTAL_1="28" TOTAL_2="82" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.548328644840707" CI_START="0.01891890937268213" EFFECT_SIZE="0.4021505376344086" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.9318812104851474" LOG_CI_START="-1.7231039031920572" LOG_EFFECT_SIZE="-0.39561134635345496" MODIFIED="2012-03-15 18:57:01 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="1.5595513981622604" STUDY_ID="STD-Schiffman-2010" TOTAL_1="46" TOTAL_2="95" VAR="2.4322005635098614" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-15 18:57:02 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.0" STUDY_ID="STD-White-2007" TOTAL_1="22" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-03-15 18:57:52 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Recurrence</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="53" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-03-15 18:57:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="249" TOTAL_2="548" WEIGHT="0.0" Z="0.0">
<NAME>Marginal recurrence</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>HR</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RFA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HR</GRAPH_LABEL_2>
<DICH_DATA CI_END="28.7530646146275" CI_START="3.6727447185321287" EFFECT_SIZE="10.276315789473685" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="1.458684140305325" LOG_CI_START="0.5649907428876931" LOG_EFFECT_SIZE="1.011837441596509" MODIFIED="2012-03-15 18:57:13 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.5249599254967812" STUDY_ID="STD-Aloia-2006" TOTAL_1="30" TOTAL_2="150" VAR="0.27558292337758605" WEIGHT="0.0"/>
<DICH_DATA CI_END="39.72904509794088" CI_START="1.8148171938688806" EFFECT_SIZE="8.491228070175438" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.5991081267548637" LOG_CI_START="0.2588328851889783" LOG_EFFECT_SIZE="0.9289705059719211" MODIFIED="2012-03-15 18:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.7872843113652462" STUDY_ID="STD-Berber-2008" TOTAL_1="68" TOTAL_2="90" VAR="0.61981658692185" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.425643367477672" CI_START="0.8458115831761797" EFFECT_SIZE="2.823529411764706" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.9743110035896899" LOG_CI_START="-0.07272637159506332" LOG_EFFECT_SIZE="0.45079231599731334" MODIFIED="2012-03-15 18:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.6150349371021203" STUDY_ID="STD-Hur-2009" TOTAL_1="25" TOTAL_2="42" VAR="0.37826797385620914" WEIGHT="0.0"/>
<DICH_DATA CI_END="30.36555540111335" CI_START="0.7587544405380855" EFFECT_SIZE="4.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.4823812289933378" LOG_CI_START="-0.11989875424216341" LOG_EFFECT_SIZE="0.6812412373755872" MODIFIED="2012-03-15 18:57:15 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.9411871935663666" STUDY_ID="STD-Otto-2010" TOTAL_1="28" TOTAL_2="82" VAR="0.8858333333333333" WEIGHT="0.0"/>
<DICH_DATA CI_END="151.57632825694586" CI_START="2.0557249765815846" EFFECT_SIZE="17.652173913043477" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="2.180631382627833" LOG_CI_START="0.3129650124913693" LOG_EFFECT_SIZE="1.2467981975596012" MODIFIED="2012-03-15 18:57:15 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="1.0970764709157939" STUDY_ID="STD-Park-2008" TOTAL_1="30" TOTAL_2="59" VAR="1.2035767830370527" WEIGHT="0.0"/>
<DICH_DATA CI_END="30.44131156851932" CI_START="1.0563670367483888" EFFECT_SIZE="5.670731707317073" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.4834633601451712" LOG_CI_START="0.023814840867303136" LOG_EFFECT_SIZE="0.7536391005062373" MODIFIED="2012-03-15 18:57:16 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.8574047656005196" STUDY_ID="STD-Schiffman-2010" TOTAL_1="46" TOTAL_2="95" VAR="0.735142932074482" WEIGHT="0.0"/>
<DICH_DATA CI_END="662.9349895042232" CI_START="1.9288150027846576" EFFECT_SIZE="35.758620689655174" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.821470941551228" LOG_CI_START="0.285290575428942" LOG_EFFECT_SIZE="1.553380758490085" MODIFIED="2012-03-15 18:57:16 +0100" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="1.489764901355516" STUDY_ID="STD-White-2007" TOTAL_1="22" TOTAL_2="30" VAR="2.2193994613108106" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="90" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-03-15 18:57:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="249" TOTAL_2="548" WEIGHT="0.0" Z="0.0">
<NAME>Intrahepatic recurrence</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>HR</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RFA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HR</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.594907183510382" CI_START="0.31990487446534993" EFFECT_SIZE="0.9111111111111111" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="27" LOG_CI_END="0.4141218283077233" LOG_CI_START="-0.49497914241893964" LOG_EFFECT_SIZE="-0.04042865705560819" MODIFIED="2012-03-15 18:57:29 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.534010410327224" STUDY_ID="STD-Aloia-2006" TOTAL_1="30" TOTAL_2="150" VAR="0.2851671183378501" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2907009949094355" CI_START="0.5405166305958784" EFFECT_SIZE="1.1127272727272728" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.3599684044510343" LOG_CI_START="-0.26719093914839953" LOG_EFFECT_SIZE="0.04638873265131737" MODIFIED="2012-03-15 18:57:30 +0100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.3683965029191268" STUDY_ID="STD-Berber-2008" TOTAL_1="68" TOTAL_2="90" VAR="0.1357159833630422" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.425643367477672" CI_START="0.8458115831761797" EFFECT_SIZE="2.823529411764706" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.9743110035896899" LOG_CI_START="-0.07272637159506332" LOG_EFFECT_SIZE="0.45079231599731334" MODIFIED="2012-03-15 18:57:31 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.6150349371021203" STUDY_ID="STD-Hur-2009" TOTAL_1="25" TOTAL_2="42" VAR="0.37826797385620914" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.324417369958534" CI_START="1.1263362718026557" EFFECT_SIZE="3.5714285714285716" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="1.0540158672393034" LOG_CI_START="0.05166807007625839" LOG_EFFECT_SIZE="0.5528419686577808" MODIFIED="2012-03-15 18:57:31 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.5887840577551897" STUDY_ID="STD-Otto-2010" TOTAL_1="28" TOTAL_2="82" VAR="0.3466666666666666" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.104117276130339" CI_START="1.3895770845968263" EFFECT_SIZE="3.7470588235294118" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="1.00449837833119" LOG_CI_START="0.14288264358296307" LOG_EFFECT_SIZE="0.5736905109570765" MODIFIED="2012-03-15 18:57:31 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.5061173476577816" STUDY_ID="STD-Park-2008" TOTAL_1="30" TOTAL_2="59" VAR="0.25615476960014777" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.855972323033663" CI_START="1.040921735968603" EFFECT_SIZE="2.6714285714285713" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.8360690557094799" LOG_CI_START="0.017418077335004258" LOG_EFFECT_SIZE="0.4267435665222421" MODIFIED="2012-03-15 18:57:32 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.48087963708486603" STUDY_ID="STD-Schiffman-2010" TOTAL_1="46" TOTAL_2="95" VAR="0.23124522536287245" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1390785020225411" CI_START="0.015054735952481486" EFFECT_SIZE="0.13095238095238096" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.05655365544028136" LOG_CI_START="-1.8223268572475946" LOG_EFFECT_SIZE="-0.8828866009036566" MODIFIED="2012-03-15 18:57:32 +0100" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="1.1036637137613945" STUDY_ID="STD-White-2007" TOTAL_1="22" TOTAL_2="30" VAR="1.218073593073593" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-03-15 18:57:52 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="87" TOTAL_2="228" WEIGHT="0.0" Z="0.0">
<NAME>Marginal and intrahepatic recurrence</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>HR</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RFA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HR</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.743083084389039" CI_START="0.299151703404288" EFFECT_SIZE="1.1911764705882353" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.6760607322368719" LOG_CI_START="-0.524108519892045" LOG_EFFECT_SIZE="0.07597610617241343" MODIFIED="2012-03-15 18:57:44 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.704985359634138" STUDY_ID="STD-Lee-2008" TOTAL_1="37" TOTAL_2="116" VAR="0.4970043572984749" WEIGHT="0.0"/>
<DICH_DATA CI_END="227.41981808666702" CI_START="0.3561694872569633" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.3568283078040237" LOG_CI_START="-0.4483432889253736" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2012-03-15 18:57:45 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="1.6477716817421992" STUDY_ID="STD-Otto-2010" TOTAL_1="28" TOTAL_2="82" VAR="2.7151515151515153" WEIGHT="0.0"/>
<DICH_DATA CI_END="34.18680290786579" CI_START="0.2460013597254221" EFFECT_SIZE="2.9" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.5338584882082902" LOG_CI_START="-0.6090624924103781" LOG_EFFECT_SIZE="0.4623979978989561" MODIFIED="2012-03-15 18:57:45 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="1.2587623916453374" STUDY_ID="STD-White-2007" TOTAL_1="22" TOTAL_2="30" VAR="1.5844827586206898" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-03-15 18:59:51 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-01-03 19:21:41 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-12-25 22:10:48 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-12-25 22:09:13 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-08-13 18:26:47 +0200" MODIFIED_BY="[Empty name]">Search strategy Cochrane Library</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-25 22:09:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Search history (14 searches) (97 hits in CENTRAL)</B>
</P>
<P>#1        (radiofrequency ablation) or (radio frequency) <B>730</B>
</P>
<P>#2        MeSH descriptor Catheter Ablation explode all trees <B>750</B>
</P>
<P>#3        (catheter ablation) <B>859</B>
</P>
<P>#4        (rfta) or (RFA) <B>124</B>
</P>
<P>#5        (thermoablati*) or (thermo ablation) or (thermo destruc*) or (thermal destruc*) or (thermo coag*) or (thermal </P>
<P> coag*) or (electrocoagulation) or (transvenous ablati*) <B>743</B>
</P>
<P>#6        (#1 OR #2 OR #3 OR #4 OR #5) <B>1829</B>
</P>
<P>#7        MeSH descriptor Colorectal Neoplasms explode all trees <B>3929</B>
</P>
<P>#8        (colorectal tumo*) or (colorectal adenom*) or (colorectal anastomos*) or (colorectal cancer*) or (colorectal </P>
<P> carcinom*) <B>4968</B>
</P>
<P>#9        (#7 OR #8) <B>6091</B>
</P>
<P>#10      MeSH descriptor Liver Neoplasms explode all trees <B>1412</B>
</P>
<P>#11      (liver tumo*) or (liver neoplas*) or (liver malign*) or (liver carcinom*) or (liver metastas*) <B>4651</B>
</P>
<P>#12      (#10 OR #11) <B>4660</B>
</P>
<P>#13      (#9 OR #12) <B>10050</B>
</P>
<P>#14      (#6 AND #13) <B>174</B>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-12-25 22:10:03 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-08-13 18:28:13 +0200" MODIFIED_BY="[Empty name]">Search strategy Medline</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-25 22:10:03 +0100" MODIFIED_BY="[Empty name]">
<P>[mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>Numbers of results/hits are marked.</P>
<P> </P>
<P>Search History  (25 searches)</P>
<P>#1        (radiofrequency or radio frequency).mp. <B>17226</B>
</P>
<P>#2        exp Catheter Ablation/ <B>14901</B>
</P>
<P>#3        catheter ablation.mp. <B>15814</B>
</P>
<P>#4        (rfta or RFA).mp. <B>1977</B>
</P>
<P>#5        (thermoablati* or thermo ablation or thermo destruc* or thermal destruc* or thermo coag* or thermal coag* or </P>
<P> electrocoagulation or transvenous ablati*).mp. <B>10901</B>
</P>
<P>#6        1 or 2 or 3 or 4 or 5 <B>34600</B>
</P>
<P>#7        (colorectal tumor or colorectal adenoma or colorectal anastomosis or colorectal cancer or colorectal </P>
<P> carcinoma).mp. <B>44163</B>
</P>
<P>#8        exp Colorectal Neoplasms/ <B>118998</B>
</P>
<P>#9        7 or 8 <B>124719</B>
</P>
<P>#10      (liver tumo* or liver neoplas* or liver malign* or liver carcinom* or liver metastas*).mp. <B>106605</B>
</P>
<P>#11      exp Liver Neoplasms/ <B>104808</B>
</P>
<P>#12      10 or 11 <B>109944</B>
</P>
<P>#13      9 or 12 <B>223706</B>
</P>
<P>#14      6 and 13 <B>3280</B>
</P>
<P>#15      randomized controlled trial.pt. <B>296353</B>
</P>
<P>#16      controlled clinical trial.pt. <B>82155</B>
</P>
<P>#17      randomized.ab. <B>203174</B>
</P>
<P>#18      placebo.ab. <B>120958</B>
</P>
<P>#19      clinical trial.sh. <B>464145</B>
</P>
<P>#20      randomly.ab. <B>147698</B>
</P>
<P>#21      trial.ti. <B>87724</B>
</P>
<P>#22      15 or 16 or 17 or 18 or 19 or 20 or 21 <B>749470</B>
</P>
<P>#23      humans.sh. <B>11356093</B>
</P>
<P>#24      22 and 23 <B>683939</B>
</P>
<P>#25      14 and 24 <B>349</B>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-12-25 22:10:48 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-08-13 18:28:35 +0200" MODIFIED_BY="[Empty name]">Search strategy EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-25 22:10:48 +0100" MODIFIED_BY="[Empty name]">
<P>[mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>Numbers of results/hits are marked.</P>
<P>
<B> </B>
</P>
<P>Search History  (28 searches)</P>
<P>#1        exp catheter ablation/ or exp radiofrequency ablation/ or exp radiofrequency/ 14901 </P>
<P>#2        (radiofrequency ablation or radiofrequency or rfta or RFA or catheter ablation or thermoablati* or thermo </P>
<P> ablation or thermo destruc* or thermal destruc* or thermo coag* or thermal coag* or electrocoagulation or </P>
<P> transvenous ablati*).mp. <B>32080</B>
</P>
<P>#3        exp COLORECTAL TUMOR/ or exp COLORECTAL CARCINOMA/ or exp COLORECTAL CANCER/ <B>118998</B>
</P>
<P>#4        (colorectal tumor or colorectal tumour or colorectal cancer or colorectal carcinoma).mp. <B>43452</B>
</P>
<P>#5        exp LIVER TUMOR/ or exp LIVER METASTASIS/ or exp LIVER CANCER/ or exp LIVER CARCINOMA/ <B>104808</B>
</P>
<P>#6        (liver tumor or liver tumour or liver carcinom* or liver metastas*).mp. <B>16153</B>
</P>
<P>#7        1 or 2 <B>32080</B>
</P>
<P>#8        3 or 4 <B>124441</B>
</P>
<P>#9        5 or 6 <B>108901</B>
</P>
<P>#10      8 or 9 <B>222404</B>
</P>
<P>#11      7 and <B>10 3181</B>
</P>
<P>#12      randomized controlled trial/ <B>296353</B>
</P>
<P>#13      randomization/ <B>69403</B>
</P>
<P>#14      controlled study/ <B>0</B>
</P>
<P>#15      multicenter study/ <B>123557</B>
</P>
<P>#16      phase 3 clinical trial/ <B>0</B>
</P>
<P>#17      phase 4 clinical trial/ <B>0</B>
</P>
<P>#18      double blind procedure/ <B>0</B>
</P>
<P>#19      single blind procedure/ <B>0</B>
</P>
<P>#20      ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).ti,ab. <B>105108</B>
</P>
<P>#21      (random* or cross* over* or factorial* or placebo* or volunteer*).ti,ab. <B>661640</B>
</P>
<P>#22      17 or 14 or 18 or 20 or 13 or 19 or 15 or 12 or 21 or 16 <B>838582</B>
</P>
<P>#23      "human*".ti,ab. <B>1559981</B>
</P>
<P>#24      (animal* or nonhuman*).ti,ab. <B>655845</B>
</P>
<P>#25      24 and 23 <B>144389</B>
</P>
<P>#26      24 not 25 <B>511456</B>
</P>
<P>#27      22 not 26 <B>807509</B>
</P>
<P>#28      11 and 27 <B>254</B>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included in quantitative synthesis (meta-analysis)&lt;br&gt;(n = 18)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included in qualitative synthesis&lt;br&gt;(n = 18)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full-text articles assessed for eligibility&lt;br&gt;(n =&amp;#160; 38)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records screened&lt;br&gt;(n = 507)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records after duplicates removed&lt;br&gt;(n =&amp;#160; 507)&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records identified through database searching&lt;br&gt;(n =&amp;#160; 1144 )&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Additional records identified through other sources&lt;br&gt;(n =&amp;#160; 2)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Records excluded&lt;br&gt;(n = 469)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Full-text articles excluded, with reasons&lt;br&gt;(n = 20)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>